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CHAPTER - I  
INTRODUCTION 
ORAL MUCOSAL DRUG DELIVERY SYSTEM 
Oral mucosal drug delivery system is widely applicable as novel site for 
administration of drug for immediate and controlled release action by preventing first 
pass metabolism and enzymatic degradation due to GI microbial flora. It is subdivided 
into buccal and sublingual in which buccal cavity is widely applicable for drug 
administration through mucosa in case of sublingual route mostly useful for fastest 
onset of action as in the case of angina pectoris. 
The buccal mucosa lines the inner cheek and buccal formulations are placed in 
the mouth between the upper gingival (gums) and cheek to treat local and systemic 
conditions. The buccal route provides one of the potential routes for typically large, 
hydrophilic and unstable proteins, oligo nucleotides and polysaccharides, as well as 
conventional small drug molecules. The oral cavity has been used as a site for local 
and systemic drug delivery. (Radha bhati et al., 2012)  
Advantages 
 Improved patient compliance due to the elimination of associated pain with 
injections; administration of drugs in unconscious or incapacitated patients; 
convenience of administration as compared to injections or oral medications. 
 A relatively rapid onset of action can be achieved relative to the oral route, 
and the formulation can be removed if therapy is required to be continued. 
 Increased easy of administration. 
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 The large contact surface of the oral cavity contributes to rapid and extensive 
drug absorption. 
Limitations 
 For local action the rapid elimination of drugs due to the flushing action of 
saliva or the ingestion of food stuffs may lead to the requirement for frequent 
dosing. 
 The non uniform distribution of drugs within saliva on release from a solid or 
semisolid delivery system could mean that some areas of the oral cavity may 
not receive effective level. 
 For both local and systemic action, patient acceptability in terms of taste, 
irritancy and ‘mouth feel’ is an issue. (Radha bhati et al., 2012). 
OVERVIEW OF ORAL MUCOSA 
The oral cavity comprises the lips, cheek, tongue, hard palate, soft palate and 
floor of the mouth. The lining of the oral cavity is referred to as the oral mucosa, and 
includes the buccal, sublingual, gingival, palatal and labial mucosa. The top quarter to 
one third of the oral mucosa is made up of closely compacted epithelial cells. The oral 
mucosa also contains many sensory receptors including the receptors of the tongue.  
Three types of oral mucosa can be found in the oral cavity; the lining mucosa 
is found in the outer oral vestibule (the buccal mucosa) and the sublingual region 
(floor of the mouth). The specialized mucosa is found on the dorsal surface of tongue, 
while the masticatory mucosa is found on the hard palate (upper surface of the mouth) 
and the gingival (gums). The masticatory mucosa is located in the regions particularly 
susceptible to the stress and strains resulting from masticatory activity. The superficial 
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cells of the masticatory mucosa are keratinized, and a thick lamina propia tightly 
binds the mucosa to the underlying periosteum. Lining mucosa on the other hand is 
not nearly as subject to masticatory loads and consequently, has a non-keratinized 
epithelium, which sits on a thin and elastic lamina propia and sub mucosa. The 
mucosa of the dorsum of the tongue is a specialized gustatory mucosa, which has well 
papillated surfaces which are both keratinized and some non-keratinized. (Srivastava 
saurakh et al., 2012)  
 
 
Figure 1: Schematic representation of the different linings of mucosa in mouth 
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FAST DISSOLVING TABLETS 
 Dysphagia or difficulty in swallowing is common among all age groups. 
Dysphagia is common in about 35% of the general population, as well as additional 
30-40% of elderly institutionalized patients and 18-22% of all persons in long term 
care facilities. This disorder is also associated with a number of pathological 
conditions including stroke, Parkinson’s disease, neurological disorders, AIDS etc. 
Parkinsonism, motion sickness, unconsciousness, elderly patients, children, mentally 
disabled persons, unavailability of water. Common complaints about the difficulty in 
swallowing tablets in the order of frequency of complaints are size, surface, form, and 
taste of tablets. Geriatric and pediatric patients and travelling patients who may not 
have ready access to water are most in need of easy swallowing dosage forms. 
 The tablets is the most widely used dosage form existing today because of its 
convenience in terms of self administration, compactness and ease in manufacture. 
However, geriatric, pediatric and mentally ill patients experiences difficulty in 
swallowing conventional tablets, which leads to poor patient compliance. To 
overcome these problems, scientists have developed innovative drug delivery system 
known as mouth dissolving / disintegrating tablets (MDTs) rapimelts are also called 
as orodispersible tablets, quick disintegrating tablets, mouth dissolving tablets, fast 
disintegrating tablets, fast dissolving tablets, rapid dissolving tablets, porous tablets, 
and orally disintegrating tablets.  However, of all the above terms, United States 
Pharmacopoeia (USP) approved these dosage forms as rapimelts. Recently, European 
Pharmacopoeia has used the terms orodispersible tablet for tablets that disperses 
readily and within 3min in mouth before swallowing. 
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 Fast dissolving tablets are those when put on tongue disintegrate 
instantaneously releasing the drug which dissolve or disperses in the saliva. Some 
drugs are absorbed from the mouth, pharynx and oesophagus as the saliva passes 
down into the stomach. In such cases, bioavailability of drug is significantly greater 
than those observed from conventional tablets dosage form. Their growing 
importance was underlined recently when European pharmacopoeia adopted the term 
“orodispersibles tablet” as a tablet that to be placed in the mouth where it disperses 
rapidly before swallowing. The bioavailability of some drugs maybe increased due to 
absorption of drug in oral cavity and also due to pregastric absorption of saliva 
containing dispersed drugs that pass down into the stomach. (Mangal mohit et al., 
2012) 
Advantages 
 Administration without water. 
 Convenience of administration. 
 Accurate dosing as compare to liquids. 
 Easy portability. 
 Ideal for pediatrics and geriatric patients. 
 Rapid dissolution/absorption of the drug, which may produce rapid onset of 
action (Brahma reddy D.R. et al., 2011). 
Disadvantages 
 Fast dissolving tablet is hygroscopic in nature so must keep in dry place. 
 Fast dissolving tablet requires special packaging for properly stabilization and 
safety of stable product (Ashish.P. et al., 2011). 
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Limitations 
 The tablets usually have insufficient mechanical strength. Hence careful 
handling is required. 
  Drugs with relatively larger doses are difficult to formulate into FDT e.g. 
antibiotics like ciprofloxacin with adult dose tablet containing about 500mg of 
the drug. 
 The tablets may leave unpleasant taste and/or grittiness in mouth if not 
formulated properly (Mangal mohit et al., 2012 and Alok kumar gupta et al., 
2011). 
Desired criteria for mouth dissolving drug delivery system 
 Mouth dissolving tablet should not require water to swallow, but it should 
dissolve or disintegrate in the mouth within matter of seconds. 
 Be compatible with taste masking. 
 Be portable without fragility concern. 
 Have a pleasing mouth feel. 
 Leave minimal or no residue in the mouth after oral administration. 
 Ease of administration to patients who refuse to swallow a tablet, such as 
pediatric and geriatric patients and psychiatric patients. 
 Rapid dissolution and absorption of drug, which may produce rapid onset of 
action. 
 Convenience of administration and accurate dosing as compared to liquids 
(Raja shree panigrahi et al., 2010). 
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Technologies used for manufacturing of MDTs 
1. Lyophilization or freeze drying 
 A process in which water is sublimed from the product after freezing. 
Lyophilization is a pharmaceutical technology which allows drying of heat sensitive 
drugs and biological at low temperature under conditions that allow removal of water 
by sublimation. Lyophilization results in preparations, which are highly porous, with a 
very high specific surface area, which dissolve rapidly and show improved absorption 
and bioavailability. 
2. Molding 
 In this method, molded tablets are prepared by using water soluble ingredients 
so that the tablets dissolve completely and rapidly. The powder blend is moistened 
with a hydro alcoholic solvent and is molded into tablets under pressure lower than 
that used in conventional tablet compression. The solvent is then removed by air 
drying. Molded tablets are very less compact than compressed tablets. These posses 
porous structure that enhances dissolution (Rakesh kumar bhasin et al, 2011). 
3. Cotton candy process 
 This process is named as it utilizes a unique spinning mechanism to produce 
floss like crystalline structure, which mimic cotton candy. Cotton candy process 
involves formation of matrix of polysaccharides or saccharides by simultaneous 
action of flash melting and spinning. The matrix formed is partially recrystallized to 
have improved flow properties and compressibility. This candy floss matrix is then 
milled and blended with active ingredients and excipients and subsequently 
compressed to MDTs (Alok kumar gupta et al., 2011). 
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4. Spray drying 
 Spray drying can produce highly porous and fine powders that dissolve 
rapidly. The formulations are incorporated by hydrolyzed gelatins as supporting 
agents, mannitol as bulking agent, sodium starch glycolate or crosscarmellose sodium 
as disintegrating and in acidic material(eg. citric acid) and or alkali material (eg. 
Sodium bicarbonate) to enhance disintegration and dissolution. Tablet compressed 
from the spray dried powder disintegrated within 20seconds when immersed in an 
aqueous medium (Rakesh kumar bhasin et al., 2011). 
5. Mass extrusion 
 This technology involves softening the active blend using the solvent mixture 
of water soluble poly ethylene glycol, using methanol and expulsion of softened mass 
through the extruder or syringe to get a cylinder of the product into even segments 
using heated blade to form tablets. The dried cylinder can also be used to coat 
granules of bitter tasting drugs and thereby masking their bitter taste (Pooja mathur et 
al., 2010). 
6. Sublimation 
 The slow dissolution of the compressed tablet containing even highly water 
soluble ingredients is due to the low porosity of the tablets. Inert solid ingredients that 
volatilize readily (eg. Urea, ammonium carbonate, ammonium bicarbonate, hexa 
methylene tetramine, camphor etc) were added to the other tablet ingredients and the 
mixture is compressed into tablets. The volatile materials were then removed via 
sublimation, which generates porous structures. Additionaly, several solvents (eg. 
 
CHAPTER  I                                                                                      INTRODUCTION 
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	9	
 
Cyclohexane, benzene) can be also used as pore forming agents (Ashish. P et al., 
2011). 
7. Nanonization 
 A recently developed nanomelt technology involves reduction in the particle 
size of drug to nano size by wet milling technique. Surface adsorption of the 
nanocrystals of the drug is done on selected stabilizers for stabilizing them against 
agglomeration, which are then incorporated into MDTs. This technique is mainly 
advantageous for poor water soluble drugs and also for a wide range of doses (upto 
200mg of drug per unit). 
8. Direct compression 
 Direct compression method is the easiest way to manufacture tablets. 
Conventional equipment, commonly available excipients and a limited number of 
processing steps are involved in direct compression. Also high doses can be 
accommodated and final weight of tablet can easily exceed that of other production 
method. Directly compressed tablet’s disintegration and solubilization depends on 
single or combined action of disintegrants, water soluble excipients and effervescent 
agent (Alok kumar gupta et al., 2011). 
Patented technologies for fast dissolving tablets 
 Zydis technology. 
 Orasolve technology. 
 Durasolv technology. 
 Flashdose technology. 
 Shearform technology. 
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 Wowtab technology. 
 Flashtab technology. 
 Dispersible tablet technology. 
 Frosta technology. 
 Pharmaburst technology. 
 Ora quick technology. 
 Quick Dis technology. 
 Nano crystal technology. 
 Ziplets/ Advatab technology. 
 Ceform technology. 
 Quick solv technology. 
 Lyo technology. 
 
Zydis technology 
 This technology involves softening the active blend using the solvent mixture 
of water soluble poly ethylene glycol using methanol and expulsion of softened mass 
through the extruder or syringe to get a cylinder of the product into even segments 
using heated blade to form tablets. The dried cylinder can also be used to coat 
granules of bitter tasting drugs and thereby masking their bitter taste. 
Orosolv technology 
 Orosolv technology has been developed by “CIMA” labs. In this system active 
medicament is taste masked. It also contains effervescent disintegrating agent. Tablets 
are made by direct compression technique at low compression force inorder to 
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minimize oral dissolution time. Conventional blenders and tablet machine is used to 
produce the tablets. The tablets produced are soft and friable and packaged in 
specially designed pick and place system (Srivastava saurabh et al., 2012 and Nishtha 
tiwari et al., 2012). 
Durosolv technology 
 Durosolv is the patented technology of “CIMA” labs. The tablets made by this 
technology consist of a drug, fillers and lubricant. Tablets are prepared by using 
conventional tableting equipment and have good rigidity. These can be packed into 
conventional packaging system like blisters. Durosolv is an appropriate technology 
for products requiring low amounts of active ingredients (Ashish .P et al., 2011 and 
Rajashree panigrahi et al., 2010). 
Flashdose technology 
 Flashdose technology has been patented by “FUISZ” nurofen meltlet, a new 
form of ibuprofen as melt in mouth tablets, prepared using flashdose technology is the 
first commercial product launched by “Bioavail Corporation”. Flash dose tablets 
consist of self binding shearform matrix termed as “FLOSS”. Shear form matrices are 
prepared by flash heat processing (Alok kumar gupta et al., 2011 and Pooja mathur et 
al., 2010). 
Shearform technology 
 It’s based on preparation of floss that is known as shearform matrix, which is 
produced by subjecting a feedstock containing a sugar carrier by flash heat 
processing. In this process, sugar is simultaneous subjected to centrifugal force and to 
a temperature gradient, which raises the temperature of the mass to create an internal, 
 
CHAPTER  I                                                                                      INTRODUCTION 
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	12	
 
flow condition, which permits part of it to move with respect of mass. The flowing 
mass exists through the spinning head that flings the floss. The floss so produced is 
amorphous in nature so it is further chopped and recrystalised by various techniques 
to provide uniform flow properties and thus facilitate blending. The recrystalised 
matrix is then blended with other tablet excipients and an active ingredient. The 
resulting mixture is compressed into tablet. The active ingredient and other excipients 
canbe blended with floss before carrying out recrystallisation. The shearform floss, 
when blended with the coated or uncoated microspheres, is compressed into flash 
dose or EZ chew tablets (Srivastava saurabh et al., 2012). 
Wowtab technology 
 Yamanouchi’s WOWTABR (without water) technology employs a 
combination of saccharides to produce fast dissolving tablets using conventional 
granulation , blending, drying and direct compression of tablets. Taste masking is 
provided by the combination of one or more sugar like excipients or 
microencapsulation of the active ingredients. These tablets exhibit significant 
hardness allowing packaging in conventional bottles or blisters. 
Flashtab technology 
 Prographarm laboratories have patented the flashtab technology. Tablet 
prepared by this system consists of an active ingredient in the form of micro crystals. 
Drug micro granules maybe prepared by using the conventional techniques like 
coacervation, micro encapsulation and extrusion spheronisation. All the processing 
utilized conventional tabletting technology. 
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Dispersible tablet technology 
 Lek, Yugoslavia patents this technology. It offers development of MDTs with 
improved dissolution rate by incorporating 8-10% of organic acids and disintegrating 
agents. Disintegrating agent facilitates rapid swelling and good wetting capabilities to 
the tablets that results in quick disintegration. Disintegrants include starch, modified 
starches, micro crystalline cellulose, alginic acid, cross linked sodium carboxy methyl 
cellulose and cyclo dextrins combination of disintegrants improves disintegration of 
tablets usually less than 1minute. 
Frosta technology 
 This technology patents by akina. It utilizes the concept of formulating plastic 
granules and compressing at low pressure to produce strong tablets with high 
porosity. Plastic granules composed of: porous and plastic material, water penetration 
enhancer and binder. The process involves usually mixing the porous plastic material 
with water penetration enhancer and followed by granulating with binder. The tablets 
obtained have excellent hardness and rapid disintegration time ranging from 15 to 30 
sec depending on size of tablet. 
Pharmaburst technology 
 SPI pharma, new castle, patents this technology. It utilizes the coprocessed 
excipients to develop MDTs, which dissolves within 30-40 s. This technology 
involves dry blending of drug, flavor, and lubricants followed by compression into 
tablets. Tablets obtained have sufficient strength so they can be packed in blister 
packs and bottles. 
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Oroquick technology 
 The oraquick ODT formulation utilizes a patented taste masking technology 
by KV pharmaceutical company, who claims that its taste masking technology ie. 
Microsphere technology (micromask) has superior mouth feel over taste masking 
alternatives. The taste masking process doesnot utilize solvents of anykind and 
therefore leads to faster and superior efficient production. Tablet with significant 
mechanical strength without distrupting taste masking are obtained after compression. 
Oraquick claims quick dissolution in matter of seconds with good taste masking. 
There are no products yet in the market using oraquick technology, but KV 
pharmaceutical has products, having different classes of drugs such as analgesics, 
cough and cold, psychotics and anti infective, in developmental stage (Rajashree 
panigrahi et al., 2010).  
Quick-dis technology 
 Lavipharm has invented an ideal intra – oral mouth dissolving drug delivery 
system, which satisfies the unmet needs of the market. The novel intra-oral drug 
delivery system, trademarked Quick –Dis TM, is Lavipharms” proprietary patented 
technology and is a thin, flexible, and quick dissolving film. The film is placed on the 
top or the floor of the tongue. It is retained at the site of application and rapidly 
releases the active agent for local and or systemic absorption. The typical 
disintegration time is only 5 to 10 seconds for the Quick-Dis TM film with a thickness 
of 2mm. the dissolving time is around 30 seconds for Quick DisTM film with a 
thickness of 2mm. 
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Nanocrystal technology 
 This is patented by Elan, King of Prussia. Nano crystal technology includes 
lyophilization of colloidal dispersions of drug substance and water soluble ingredients 
filled into blisters pockets.this method avoids manufacturing process such as 
granulation, blending and tabletting which is more advantages for highly potent and 
hazardous drugs. As manufacturing losses are negligible, this process is useful for 
small quantities of drug. 
Ziplets/advatab technology 
 It utilizes water insoluble ingredient combined with one or more effective 
disintegrants to produce MDT with improved mechanical strength and optimal 
disintegration time at low compression force. 
Ceform technology 
 This technology involves preparation of microspheres of active drugs. Drug 
material alone or in combination with other pharmaceutical substance and excipients 
is placed into a precision engineered rapid spinning machine. The centrifugal force 
comes into action, which throw the dry drug blend at high speed through small heated 
openings. Due to the heat provided by carefully controlled temperature, drug blend 
liquefies to form a sphere, without affecting the drug stability. The microspheres are 
thus formed are compressed into tablets. As the drugs and excipients both can be 
processed simultaneously, it create a unique micro environment in which the material 
can be incorporated into the microspheres that can alter the characteristics of the drug, 
such as enhancing solubility and stability. 
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Quicksolv technology 
 This technology used two solvents in formulating a matrix, which 
disintegrates instantly. Methodology includes dissolving matrix components in water 
and the solution or dispersion is frozen. Then dry the matrix by removing water using 
excess of alcohol (solvent extraction). Thus the product formed has uniform porosity 
and adequate strength for handling. 
Lyo technology 
 Lyo technology is patented by pharmalyoc. Oil in water emulsion is prepared 
and placed directly into blister cavities followed by freeze drying. Non homogeneity 
during freeze drying is avoided by incorporating inert filler to increase the viscosity 
finally the sedimentation. High proportion of filler reduces porosity of tablets due to 
which disintegration is lowered (Srivastava saurabh et al., 2012). 
Ingredients to be used for fast disintegrating tablet 
 Important ingredients that are used in the formulation of fast disintegrating 
tablets should allow quick release of the drug, resulting in faster dissolution. This 
includes both the active and inactive ingredients excipients balance the properties of 
the actives in fast disintegrating tablets. 
Binders 
 The choice of a binder is critical in a fast dissolving formulation for achieving 
the desired sensory and melting characteristics, and for the faster release of active 
ingredients. Binders keep the composition of these fast dissolving tablets together 
during the compression stage. The right selection of a binder or combination of 
 
CHAPTER  I                                                                                      INTRODUCTION 
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	17	
 
binders is essential to maintain the integrity and stability of the tablet. Binders can 
either be liquid, semisolid, solid or mixtures of varying molecular weights such as 
poly ethylene glycol. 
Lubricants 
 Lubrications are used for to reduce the friction during compaction and ejection 
of tablets in present study magnesium stearate and talc were used as lubricant.(eg) 
stearic acid, magnesium stearate, poly ethylene glycol, liquid paraffin, magnesium 
lauryl sulfate (Brahma reddy D.R et al., 2011). 
Bulking agent 
 The material contributes functions of a diluents, filler and cost reducer. 
Bulking agents improve the textural characteristics that in turn enhance the 
disintegration in the mouth, besides; adding bulk also reduces the concentrations of 
the active in the composition. The recommended bulking agents for this delivery 
system should be more sugar based such as mannitol, poly dextrose, lactate and starch 
hydrolysate for higher aqueous solubility and good sensory perception. 
Emulsifying agents 
 Emulsifying agents are important excipients for formulating fast melting 
tablets, they aid in rapid disintegration and drug release without chewing, swallowing 
or drinking water. In addition, incorporating emulsifying agents is useful in stabilizing 
the immiscible blends and enhancing bioavailability. A wide range of emulsifiers is 
recommended for fast tablet formulation, including alkyl sulfates. 
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Flavours and sweetners 
 Flavours are peppermint, aromatic oil, clove oil, anise oil, eucalyptus oil 
thyme oil, vanilla, citrus oil. The addition of these ingredients assists in overcoming 
bitterness and undesirable tastes of some active ingredients. Formulators can choose 
from a wide range of sweeteners including sugar, dextrose and fructose, as well as 
non nutritive sweeteners such as aspartame, sugar alcohols and sucralose (Brahma 
reddy D.R et al., 2011). 
Role of superdisintegrants 
 As days passes, demand for faster disintegrating formulation is increased. So 
pharmacist needs to formulate disintegrants ie.,super disintegrants which are effective  
at low concentration and have greater disintegrating efficiency and they are more 
effective intragranularly. But have one drawback that it is hygroscopic therefore not 
used with moisture sensitive drugs. 
Mechanism of action of super disintegrants: the tablet breaks to primary particles by 
one or more of the mechanism listed below 
1. By swelling. 
2. By capillary action. 
3. Due to disintegrating particle/ particle repulsive forces. 
4. Due to deformation. 
5. Due to release of gases. 
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1. By swelling 
 Tablets with high porosity show poor disintegration due to lack of adequate 
swelling force. On the other hand, sufficient swelling force is exerted in the tablet 
with low porosity. It is worthwhile to note that if the packing fraction is very high, 
fluid is unable to penetrate in the tablet and disintegration is again slows down. 
 
 
 
Figure 2: Schematic representation of mechanism of action of super 
disintegrants by swelling 
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2. By capillary action 
 Disintegration by capillary action is always the first step. When we put the 
tablet into suitable aqueous medium, the medium penetrates into the tablet and 
replaces the air absorbed on the particles, which weakens the intermolecular bond and 
breaks the tablet into fine particles. Water uptake by tablet depends upon 
hydrophilicity of the drug/ excipient and on tabletting conditions. For these types of 
disintegrants maintenance of porous structure and low interfacial tension towards 
aqueous fluid is necessary which helps in disintegration by creating a hydrophilic 
network around the drug particles. 
3. Due to disintegrating particle/ particle repulsive forces 
 Another mechanism of disintegration attempts to explain the swelling of tablet 
made with ‘non swellable’ disintegrants. Guyot-Hermann has proposed a particle 
repulsion theory based on the observation that nonswelling particle also cause 
disintegration of tablets. The electric repulsive forces between particles are the 
mechanism of disintegration and water is required for it. Researchers found that 
repulsion is secondary to wicking. 
4. Due to deformation 
 Hess had proved that during tablet compression, disintegrated particles get 
deformed and these deformed particles get into their normal structure when they come 
in contact with aqueous media or water. Occasionally, the swelling capacity of starch 
was improved when granules were extensively deformed during compression. This 
increase in size of the deformed particles produces a breakup of the tablet. This may 
be a mechanism of starch and has only recently begun to be studied. 
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5. Due to release of gases 
 Carbondioxide released within tablets on wetting due to interaction between 
bicarbonate and carbonate with citric acid and tartaric acid. The tablet disintegrates 
due to generation of pressure within the tablet. This effervescent mixture is used when 
pharmacist needs to formulate very rapidly dissolving tablets or fast disintegrating 
tablet. As these disintegrants are highly sensitive to small changes in humidity level 
and temperature, strict control of environment is required during manufacturing of the 
tablets. The effervescent blend is either added immediately prior to compression or 
can be added in to two separate fraction of formulation (Nishtha tiwari et al., 2012). 
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CHAPTER – II 
LITERATURE REVIEW 
Bhingare C.L. et al., 2013, formulated and evaluated mouth dissolving tablets of 
zolpidem tartrate to improve bioavailability and circumvent the first pass effect by 
direct compression method using croscarmellose sodium, sodium starch glycolate as 
superdisintegrants and mannitol, microcrystalline cellulose, dicalcium phosphate as 
diluents. It could be concluded that mouth dissolving tablets of zolpidem tartrate were 
successfully formulated to improve the drug release profile. 
Kadria A. Elkhodairy et al., 2013, formulated and optimized orodispersible tablets 
of flutamide by direct compression technique using three different approaches 
namely; super disintegration, effervescence and sublimation. Different combined 
approaches were proposed and evaluated to optimize tablet characteristics. Sodium 
starch glycolate (SSG) was used as super disintegrant. The incorporation of 1:5 solid 
dispersion of FTM: PEG 6000 instead of the pure drug in the same formulation 
increased the drug release rate from 73.12 to 96.99% after 15 minutes. This increase 
in the dissolution rate may be due to the amorphization of the drug during the solid 
dispersion preparation. The presence of amorphous form of the drug was shown in the 
IR spectra. 
Kamal Saroha et al., 2013, formulated and evaluated fast dissolving tablets of  
amoxicillin trihydrate  using synthetic super disintegrants  such as sodium starch 
glycolate(SSG) and croscarmellose sodium(CCS); microcrystalline cellulose(MCC) 
as direct compressible diluents by direct compression technique. The study concluded 
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that 10% CCS showed better disintegrating property and drug release upto 99.78% 
within 25min than the most widely used synthetic superdisintegrants like SSG.  
Manish R.Bhise et al., 2013, formulated and evaluated intra orally fast dissolving 
tablet of olmesartan medoxomil were prepared by using three different 
superdisintegrants like crosscarmellose sodium, sodium starch glycolate and 
crospovidone. The results showed that 8% crosspovidone was found to be an 
optimized batch. 
Mohanthesh A.M.K. et al., 2013, formulated and evaluated mouth dissolving tablets 
norfloxacin an antibacterial agent using different superdisintegrants like sodium 
starch glycolate, crosscarmellose sodium (CCS), crospovidone by direct compression 
technique. The results revealed that the increased proportion of various 
superdisintegrants were associated with increase in the overall cumulative drug 
release rate. 
Pavan K.Rawat et al., 2013, formulated and evaluated fast dissolving tablets of 
pioglitazone hydrochloride were prepared by direct compression method using super 
disintegrants such as croscarmellose, crospovidone, indion 414. The study shows that 
the dissolution rate of pioglitazone could be enhanced to a great extent by 
combinations of superdisintegrants by direct compression technique. 
Preeti Karwa et al., 2013, developed fast dissolving tablets of losartan potassium 
were designed using super disintegrant such as kollidon CL-SF in different 
concentrations by direct compression technique. The result shown that the 
superdisintegrant disintegrate within few seconds without need of water so as to 
overcome swallowing difficulties. 
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Vishakha S.Hastak et al., 2013, formulated and evaluated fast dissolving tablets of 
gliclazide were prepared using crosscarmellose sodium and sodium starch glycolate as 
superdisintegrant separately and then in combination by direct compression method. 
The result were observed that among two superdisintegrants crosscarmellose sodium 
(5%) showed better result in disintegration time and maximum invitro drug release of 
99.89% at the end of 20 minutes. 
Anas Bahnassi et al., 2012, formulated and evaluated aceclofenac fast dissolving 
tablets using foam granulation technique. It is a newer technique that promises better 
distribution of the granulating system and better properties for the produced tablets. 
Aceclofenac was selected as the model drug. The poor hydrophilicity of the drug 
results in variable dissolution rate and poor bioavailability. This study was performed 
to prepare aceclofenac ODTs using the newer technique and various types of 
disintegrants, glidants and lubricants. It was concluded that the prepared aceclofenac 
ODTs by foam granulation technique using selective range of excipients can provide a 
dosage form with better patient compliance and effective therapy. 
Deshmukh.V.N. et al., 2012, developed and evaluated orally disintegrating tablets by 
direct compression method. Taste masking of ondansetron was carried out by adding 
trusil lemon lime ASV, peppermint powder as flavouring agent and aspartame as 
sweetening agent, using croscarmellose sodium, sodium starch glycolate, 
crospovidone as super disintegrant  while the other components were kept constant. 
Nine formulations f1-f9 were prepared by varying the concentration of super 
disintegrants. The total weight of tablet was kept constant (100mg) and drug content 
was 4mg. The formulations containing crospovidone (20%, 25%, and 30%) showed 
lowest disintegration time, wetting time and dispersion time. All the formulations 
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release more than 80% of drug within 30 minutes which prove it fast dissolving 
action. Based on dissolution rate superdisintegrants can be ranked as crospovidone > 
sodium starch glycolate > croscarmellose sodium. Among all the formulated tablets 
containing 25%crospovidone showed good compressibility, flowability and less 
friability, it also showed less disintegration, wetting time, dispersion time and 
percentage cumulative release of drug was 99.47% in 10 minutes. It was concluded 
that the ideal bitterless orally disintegrating ondansetrons tablet were prepared 
successfully. 
Devendra revanand rane et al., 2012, formulated and evaluated fast dissolving 
tablets of albendazole with a view to and provide quick onset of action. The study was 
to formulate fast dissolving tablets of albendazole to achieve a better dissolution rate 
and further improving bioavailability of the drug. FDTs were prepared by direct 
compression technique using super disintegrants in different concentrations. The 
formulation containing 5% w/w super disintegrant crospovidone and 20%w/w micro 
crystalline cellulose was considered to be the best formulation, which releases up to 
99.09% in 40 minutes. 
Hasan Mahmud Reza et al., 2012, formulated, designed and evaluated baclofen 
mouth dissolving tablets. The aim of this study was to prepare mouth dissolving 
tablets of baclofen using various super disintegrants like kollidon CL-SF, 
crospovidone, sodium starch glycolate and ludiflash by direct compression method. 
Among all the formulations tablets containing kollidon CL-SF, sodium starch 
glycolate and ludiflash showed superior organoleptic properties along with excellent 
invitro disintegration and drug release pattern as compared to that containing 
croscarmellose. It could be concluded that mouth dissolving tablets of Baclofen were 
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prepared successfully using F1 and F2 formula as they satisfy the criteria of a mouth 
dissolving tablet and would be the alternative to the currently available conventional 
tablets. 
Kusum devi et al., 2012, performed in vitro and in vivo evaluation of fast dissolving 
tablets containing solid dispersion of pioglitazone HCl. Polyvinyl pyrrolidine K30 
carrier was selected and solid dispersions were prepared by various methods. The best 
formulation has shown Tmax of 1 hour which was highly significant (p >0.01) when 
compared with pure drug and marketed formulation. Therefore, the solid dispersions 
prepared by kneading method using PVP K30 as hydrophilic carrier can be 
successfully used for improvement of dissolution of PIO and resulted in faster onset 
of action as indicated by in vivo studies. 
Ravi S. Wanare et al., 2012, formulated and evaluated fast dissolving tablets of 
azithromycin dihydrate using different super disintegrants. In this study different 
super disintegrants were used such as sodium starch glycolate, croscarmellose sodium 
and crospovidone. In all the formulations water was used as binding agent to attain 
hardness. The prepared fast disintegrating tablets were evaluated. Wetting time of 
formulation containing sodium starch glycolate was the least and tablets showed 
much faster disintegration. All the tablets had hardness of 3.1- 5.3 kg/cm2 and 
friability was less than 1%. Among all formulations FDT 7 showed least 
disintegrating time of 21.40 seconds. 
Shaikh RG. et al., 2012, designed, optimized and evaluated orally disintegrating 
tablets of antiemetic drug. The bitter taste of the drug was masked by kyron T 114, 
(weak cation exchange resin) by ion exchange resin complexation method, which was 
prepared by the batch technique. The resin ratio and pH was optimized to successfully 
 
CHAPTER II                                                                           LITERATURE REVIEW 
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	27	
 
formulate the resinate into ODT and it was confirmed by FTIR and DSC study. In 
preliminary trials, selection of super disintegrants (i.e., crospovidone XL 10, 
crosscarmellose sodium and sodium starch glycolate) and selection of diluents (i.e., 
mannitol SD 200, Avicel pH 102, Avicel pH112, starch and pregelatinized starch) 
were made.  The cohesive force of mannitol increases wetting time and disintegration 
time so drug release was delayed.  Results from an evaluation by a panel of ten human 
volunteers demonstrated that the orally disintegrating tablets prepared by kyron T 114 
improved the taste significantly. 
 Abhishek Jain et al., 2011, formulated and evaluated aceclofenac fast dissolving 
tablets using superdisintegrants such as croscarmellose sodium, crospovidone, sodium 
starch glycolate and sodium lauryl sulphate as surfactant by direct compression 
method. The tablet disintegrated within 18 to 49 seconds and almost 90% of drug was 
released from all formulations within 15 minutes. Stability studies of the tablets at 40 
± 2/75% ± 5% RH for 3 months showed non significant drug loss. The formulations 
containing 6% of croscarmellose sodium was found to be the best. 
Basawaraj S. Patil et al., 2011, formulated and evaluated fast dissolving tablets of 
tizanidine HCl by direct compression method. Super disintegrants such as 
croscarmellose sodium, sodium starch glycolate and crospovidone on wetting time, 
invitro dispersion time and stability parameter has been studied. From this study it 
was concluded that fast dissolving tablets prepared by direct compression method 
using different super disintegrants enhanced dissolution to improve bioavailability 
and effectiveness of tizanidine HCl. 
Basawaraj S Patil et al., 2011, formulated and evaluated fast dissolving tablets of 
granisetron hydrochloride by direct compression technique. Super disintegrants such 
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as croscarmellose sodium, sodium starch glycolate and crospovidone, on wetting 
time, invitro dispersion time and stability parameter has been studied. From this study 
it was concluded that fast dissolving tablets were prepared by direct compression 
method using different super disintegrants enhanced dissolution to improve 
bioavailability and effectiveness of granisetron hydrochloride. 
Bhanushali Akash K. et al., 2011, formulated and evaluated mouth dissolving tablets 
of isosorbide mononitrate using crospovidone as super disintegrant. The tablets were 
prepared by direct compression method. This technique would be an effective 
alternative approach compared with the use of more expensive adjuvant in the 
formulation of mouth dissolving tablets. It can be concluded that disintegration and 
dissolution rate of isosorbide mononitrate can be enhanced to great extent with 
addition of super disintegrants. 
Biswajit Basu et al., 2011, formulated and evaluated fast dissolving tablets of 
cinnarizine using super disintegrant blends and subliming material.  A combination of 
super disintegrants sodium starch glycolate (SSG) and crosscarmellose sodium (CCS) 
was used along with camphor as a subliming material.  An optimized concentration of 
camphor was added to aid the porosity of the tablet.  A 32 full factorial design was 
applied to investigate the combined effect of two formulation variables: amount of 
SSG and CCS.  In the present study, direct compression was used to prepare the 
tablets. Camphor was sublimed from the tablet by exposing the tablet to vaccum drier 
at 600C for 12 hours.  An optimized tablet formulation (fa) was found to have good 
hardness of 3.30±0.10 kg/cm2, wetting time of 42.33±4.04 seconds, DT of 34.67±1.53 
seconds, and cumulative drug release of not less than 99% in 16minutes. 
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Chandrasekhar Patro et al.,2011, formulated and evaluated cetirizine hydrochloride 
mouth fast dissolving tablets  using different concentrations of super disintegrants like 
crospovidone(CP), croscarmellose sodium(CCS), sodium starch glycolate 
(SSG).Tablets were prepared by direct compression method and evaluated. The 
results indicate that formulation prepared with 5% croscarmellose sodium was found 
to be optimized which provides maximum drug release (99%) and minimum 
disintegration time (less than 20 sec). Stability studies of optimized formulation 
revealed that formulation is stable. 
Himmat Singh et al., 2011, formulated and evaluated mouth dissolving tablets of 
carvedilol. The solubility of carvedilol was enhanced with different ratios of PVP by 
the solvent evaporation method. Invitro release profile of solid dispersion obtained in 
SGF without enzymes and pH6.8 phosphate buffer indicate that 100% drug release 
found within 20 minutes. This solid dispersion was directly compressed into tablets 
using crospovidone, sodium starch glycolate, and croscarmellose sodium and 
polacrilin potassium in different concentration as a super disintegrant. The prepared 
tablets containing the solid dispersion of carvedilol were found to have sufficient 
strength of 2.5-4Kg/cm2which disintegrated in the oral cavity within 21 seconds 
contain crospovidone (5%) as super disintegrant. 
Rashmi dahima et al.,2011, formulated and evaluated aceclofenac mouth dissolving 
tablets  were prepared with two different techniques, wet granulation and direct 
compression, in which different formulation were prepared with varying 
concentrations of excipients. The tablets were evaluated for the drug release profile in 
phosphate buffered saline (PBS) PH7.4. Direct compression batch C3 gave far better 
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dissolution than the wet granulation batch F2, which released only 75.37%drug and C3 
released 89.69%drug in 90 minutes. 
Ravikumar Nayek et al., 2011, formulated and evaluated fast dissolving tablets of 
lornoxicam were prepared using super disintegrants viz; crospovidone, croscarmellose 
sodium and sodium starch glycolate by direct compression method. The different 
formulations showed disintegration time between 18 to 75 seconds and drug release 
showed time between the ranges of 10 to 12 minutes. Among all the formulations, f3 
(containing 4% of crospovidone) showed 99% drug release within 12 minutes and 
disintegration time in 18 seconds. Thus F3 was considered best among the other 
formulations. The stability study was conducted as per the ICH guidelines and the 
optimized formulation (F3) was found to be stable, with insignificant change in 
hardness, drug content and disintegration time. Therefore the main objective of the 
present work is to develop orodispersible tablets of lornoxicam to improve 
bioavailability, disintegration time, dissolution efficacy and patient compliance. 
Sarasija Suresh et al., 2011, formulated, designed and optimized fast dissolving 
clonazepam tablets by sublimation method with a view to enhance patient 
compliance. Croscarmellose sodium (2-8% w/w) was used as super disintegrant and 
camphor (20-40% w/w) was used as subliming agent, to increase the porosity of the 
tablets, since it helps water to penetrate into the tablets, along with directly 
compressible mannitol to enhance mouth feel.  Based on invitro dispersion time 
(approximately 11 seconds), the formulation containing 5% w/w croscarmellose 
sodium and 40% w/w camphor was found to be show increased   invitro drug release 
(pH 6.8 phosphate buffer). The optimized tablet formulations were compared with 
conventional commercial tablet formulation drug release profiles.  This formulation 
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showed nearly nine fold faster drug release (t50% 1.8 min) compared to the 
conventional commercial tablet formulation (t50% 16.4 min).  Short term stability 
studies on the formulation indicated that there are no significant changes in drug 
content and invitro dispersion time (P0.05). 
Stoltenberg et al., 2011, formulated and evaluated orally disintegrated mini tablets 
(ODMTs) - A novel solid oral dosage forms for pediatric use. The suitability of five 
commercially available ready to use tableting excipients , ludiflash,  parteck ODTs, 
pearlitol flash, pharmaburst 500 and prosolv ODTs, to be directly compressed in to 
mini tablets, with 2mm diameter was examined. All of the excipients are based on co-
processed mannitol. Drug free ODMTs and ODMTs with a child appropriate dose of 
hydrochlorothiazide were investigated. The promising results indicated that the orally 
disintegrating mini tablets may serve as a novel platform technology for pediatric in 
future. 
Basawaraj S. Patil et al., 2010, formulated and evaluated   mouth dissolving tablets 
of nimesulide by new co processed technique. The two super disintegrants used in this 
study were croscarmellose sodium and sodium starch glycolate and using the same 
excipients the tablets were prepared without disintegrants and were evaluated in the 
similar way. From the results obtained, it can be concluded that the tablet formulation 
(P4) showed the promising formulation. 
Dinesh Mohan S. et al., 2010, formulated and evaluated salbutamol sulphate fast 
dissolving tablets were highly accepted fast growing drug delivery system. This study 
was aimed at fabricating mouth dissolving tablets which can dissolve rapidly in the 
oral cavity. Asthma is an inflammatory disorder that results in the destruction of air 
pathways and causes difficulty in breathing however other route of drug delivery 
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system such as aerosols and parenterals have rapid onset of action but strongly affect 
the patience compliance. Thus, an attempt was made to improve the onset of action of 
bronchodilator used commonly in the treatment of asthma. The tablets were prepared 
by direct compression method using super disintegrants such as primojel, kollidon 
CL, and L-hydroxy propyl cellulose and evaluated. Formulation FD 9 containing 
kollidon CL is most acceptable. The fast dissolving tablets of salbutamol sulphate 4% 
w/w and kollidon CL as the super disintegrant is an alternative to and better than the 
conventional tablet dosage form used in the management of asthma. 
 Nagendra kumar D. et al., 2010, formulated and evaluated fast dissolving 
granisetron HCL tablets using novel co-processed super disintegrants consisting of 
crospovidone and sodium starch glycolate in the different ratios (1:1, 1:2, and 1:3).  
The developed super disintegrants were evaluated in comparison with physical 
mixture of super disintegrants.  The angle of repose of the developed excipients was 
found to be 250, carr’s index in the range of 10-15% and hausner’s ratio in the range 
of 1.11-1.14.  Among the designed formulations (CP1) containing 4% w/w of co-
processed super disintegrant (1:1 mixture of crospovidone and sodium starch 
glycolate) emerged as the overall best formulation (t50% 2.0 minutes) based on drug 
release characteristics in pH 6.8 phosphate buffer compared to commercial 
conventional tablet formulation (t50% 15 minutes).  Short term stability studies on 
promising formulation indicated that there were no significant changes in drug 
content and invitro dispersion time (P 0.05). 
Puttewar T.Y. et al., 2010, formulated and evaluated orodispersible tablets of taste 
masked doxylamine succinate using ion exchange resins. The difference in drug 
release values was found to be 100.45±1.89 and 56.47±1.89 respectively. To prevent 
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the bitter taste and unacceptable odour of the drug, taste was masked with weak cation 
exchange resins like indion 234, indion 204 and indion 414. Among the three resins, 
one was selected for further studies i.e. indion 234, because of high drug loading 
capacity. Drug resin complex were prepared using batch method and effect of various 
processing parameters viz drug-resin ratio PH, temperature and drug concentration 
was studied to optimize the loading conditions. Maximum loading was obtained at 
drug resin ratio 1:2, PH 5, temp 500and drug concentration 4mg/ml. The f5 batch with 
disintegration time 25.24 ± 0.75 and dissolution 100.46% ± 3.78 was selected as 
optimized formulation and this was compared with conventional marketed 
formulation which was found to be superior. 
Sudhir Bhardwaj et al., 2010, formulated and evaluated fast dissolving tablets of 
aceclofenac using various super disintegrants (sodium starch glycolate) following by 
direct compression technique. All the formulations showed disintegration time in 
range of 12.2 to 27.5 seconds along with rapid invitro dissolution. It was concluded 
that the fast dissolving tablets of poor soluble drug can be made by direct compression 
technique using selective super disintegrants showing enhanced dissolution, taste 
masking and hence better patient compliance and effective therapy. 
Venkata ramana reddy et al., 2010, compared lyophilization and compression 
technique of risperidone oral disintegrating tablets (ODTs) using different process like 
lyophilization and compressed tablets technique. Amberlite was used as taste masking 
agent, mannitol as a diluent and peppermint as a flavouring agent. The optimized 
formulation showed good masking less disintegration time (< 30 seconds) and release 
profile with maximum drug release at all time intervals. It was concluded that 
risperidone ODT’s with improved taste masking and dissolution could be prepared by 
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both lyophilization and compressed tablet technique with suitable taste masking agent 
like amberlite. 
Vineet Bhardwaj et al., 2010, formulated and evaluated fast dissolving tablets of 
amlodipine besylate using different super disintegrants and camphor as sublimating 
agent. Different concentrations (2%, 4%, 6%) of super disintegrants such as Ac-Di -
sol, sodium starch glycolate, kollidon-CL were used. Mannitol was used as bulking 
agent. Tablets were prepared by direct compression. The compressed tablets were 
dried for 5 hours to allow sublimation of camphor to increase the porosity of the fast 
dissolving tablets to improve dissolution. All the tablets had hardness of 2.3-
3.7kg/cm2, friability was less than 1% weight variation and drug content were within 
official limit. Amongst all formulations f9 prepared by 6%Ac-Di –sol showed least 
disintegrating time of 11seconds and faster dissolution. Formulation f9 was then 
studied for accelerated stability studies as per ICH guidelines for 60 days that shows 
no remarkable change in the formulation. 
Ajay K. Banga et al., 2009, studied effects of disintegration promoting agent, 
lubricants and moisture treatment on optimized fast disintegrating tablets. Calcium 
silicate and various lubricants on an optimized β-cyclodextrin based fast 
disintegrating tablet formulations were investigated. Effects of moisture treatment 
were also evaluated at 75, 85 and 95%RH. Results of multiple linear regression 
analysis revealed that concentration of calcium silicate had no effect; however 
concentration of lubricant was found to be important for tablet disintegration and 
hardness. An optimized value of 1.5% of magnesium stearate gave disintegration time 
of 23.4s and hardness of 1.42kg. Tablet hardness was significantly affected with L-
leucine, while other lubricants had no significant effect hardness was not affected at 
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75% moisture treatment, moisture treatment at 85 and 95% increased hardness of the 
tablets; however at the same time it negatively affected the disintegration time. 
Biraju patel et al., 2009, developed and evaluated fast dissolving tablets of glipizide 
by direct compression method with a view to enhance patient compliance. Two super 
disintegrants viz, crospovidone and croscarmellose sodium (4%, 5%, 6%) with 
different binders viz, PVP K-30 and pregelatinized starch (3%) were used. The 
prepared batches of tablets were evaluated.  Based on evaluating parameters 
formulation prepared by using 5% croscarmellose sodium with 3% PVP K 30 was 
selected as optimized formulation. Finally the optimized formulation was compared 
with marketed conventional formulation. Stability studies carried out at 250c/60%RH 
and 400c/75%rh for optimized formulation for 2 months indicated that there was no 
significant change found in physical appearance, disintegration time and wetting time 
of the tablets. 
 Jain C.P. et al., 2009, formulated and evaluated fast dissolving tablets of valsartan 
using different super disintegrants by direct compression method. Effect of 
disintegrant on disintegration behavior of tablet in artificial saliva, pH5.8 was 
evaluated. Wetting time of formulations containing crospovidone was least and tablet 
showed fastest disintegration. The drug release from FDTs increased with increasing 
concentration of superdisintegrants and was found to be highest with formulation 
containing crospovidone. The release of valsartan from FDTs was found to follow 
non fickian diffusion kinetics.  
Kawtikar P.S. et al., 2009, formulated, evaluated and optimized fast dissolving 
tablets containing tizanidine hydrochloride.An attempt has been made to prepare 
bitter less fast dissolving tablets using eudragit E 100 as a taste masking agent using 
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mass extrusion technique for preparing taste masked granules. The tablet was 
prepared with three super disintegrants (e.g.) sodium starch glycolate, cross 
carmellose sodium and crospovidone. Disintegration in oral cavity tested was found to 
be 22 seconds. Other tablets were prepared by using camphor as sublimating agent. It 
was concluded that tablets prepared by addition of superdisintegrants has less 
disintegration time than those prepared by sublimation method. 
Makiko Fuji et al., 2009, studied the effects of powder characteristics on oral tablet 
disintegration. This report describes an investigation of the factors affecting 
disintegration time in the mouth (DTM) of rapidly disintegrating tablets. The relation 
between DTM of rapidly disintegrating tablets and stationary time of upper punch 
displacement (STP) was examined using a tablet process analyser (Tab all). Results 
indicated that the bulk density of mixed excipients powder used for tablet preparation 
affects both DTM and STP. As the value of bulk density increased, STP became 
longer and DTM shorter. The results of a combination of granules and powder with or 
without drug showed linear relation between apparent volume (reciprocal of bulk 
density) and DTM. For a DTM less than 60 seconds, a formulation with a bulk 
density greater 0.5g/ml should be chosen with a compression force of 5KN. The 
hardness of tablets could be greater than 3kg if at least one high compressibility 
excipients was used in the formulation. 
Sarasija suresh et al., 2009, formulated designed and optimized fast dissolving 
clonazepam tablets by direct compression method with a view to enhance patient 
compliance. Crospovidone (2-8%w/w) was used as super disintegrant and 
microcrystalline cellulose (20-40%w/w) as diluents, along with directly compressible 
mannitol to enhance mouth feel. The optimized tablet formulation was compared with 
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conventional commercial tablet formulation for drug release. This formulation 
showed nearly fivefold faster drug release (t50%3.5 min) compared to the 
conventional commercial tablet formulation (t50%16.4 minute). 
 Shirsand S.B. et al., 2008, designed and evaluated fast dissolving tablets of 
clonazepam. Three super disintegrants viz, crospovidone, croscarmellose sodium and 
sodium starch glycolate in different ratios with microcrystalline cellulose (Avicel pH 
102), along with directly compressible mannitol (pearlitol SD 200) to enhance mouth 
feel.  Among the three promising formulations, the formulation prepared by using 
10% w/w of crospovidone and 35% w/w of microcrystalline cellulose emerged as the 
overall best formulation (t50% 16.4 min).  Short term stability studies on the 
formulations indicated that there were no significant changes in drug content and 
invitro dispersion time (P < 0.05). 
Uday S. Rangole et al., 2008, formulated and evaluated rapidly disintegrating tablets 
of hydrochlorthiazide using different concentrations (2%, 3%, 4%, and 5%) of super 
disintegrants like croscarmellose sodium and crospovidone by direct compression 
method using 8mm flat punch. Disintegration time and drug release were taken as the 
basis to optimize the rapidly disintegrating tablet. Crospovidone in the concentration 
of 4% gave fastest disintegration in 16 seconds and showed 100% drug release within 
14 minutes were selected as the optimized formulation. Optimized formulation was 
subjected to stability studies for thirty days which showed stability with regards to 
release pattern. 
Abdel bary G.et al., 2005, determined the invitro disintegration profile of rapidly 
disintegrating tablets and correlation with oral disintegration. The disintegration 
profile of RDT manufactured by main commercialized technologies was evaluated 
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using the texture analyser (TA) in order to simulate as much as possible the oral 
disintegration of these dosage forms, a new operating structure was developed. This 
structure mimics the situation in the patient’s mouth and provides a gradual 
elimination of the detached particles during the disintegration process. Results 
obtained when artificial saliva at 370c was employed as disintegration medium were 
used to correlate the invitro (t2) and oral disintegration times. Excellent correlation 
was found as in addition was able to achieve a qualitative measure of the mouth feel 
by comparing the thickness of the tablets and the penetration distance obtained from 
the disintegration profile. 
Peter Christian Schmidt et al., 2002, formulated fast dispersible tablets of 
ibuprofen. A direct compression method was used to prepare these two types of 
tablets containing coated ibuprofen as a high dosed model drug. The properties of the 
water dispersible tablet such as porosity, hardness, disintegration time and increase in 
viscosity after dispersion were investigated. The selected tablet formulation 
containing 26% galactomennan and 5%, crospovidone disintegrates before the 
galactomennan starts to swell. These tablets disperse in water within 40 seconds and 
show a crushing strength of 95N. To develop an orodispersible tablet, a rotatable 
central composite design was applied to predict the effect of the quantitative factors 
mannitol and crospovidone as well as compression force on the characteristics of the 
tablet. Special emphasis was paid to the development of a wetting test, replacing the 
normal disintegration method an optimum tablet formulation containing 34%mannitol 
and 13%crospovidone ,provides a short wetting time of 17 seconds and a sufficient 
crushing strength of 40N.In conclusion fast dispersible tablets with acceptable 
hardness and desirable taste could be prepared within the optimum region. 
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Adamofini et al., 1997, developed fast dispersible/ slow releasing ibuprofen tablets to 
prevent bitter taste and side effects of the drug, the drug was associated with 
phospholipon 80H, a saturated lecithin by wet granulation. The granules were then 
coated using different film forming agents (kollicoat SR 30, amprac 01, kollidon 90f, 
eudragit RD100) obtaining four lots 1-4 coated granules were then formulated with a 
sweetner (aspartame) a mannitol based diluent (pearlitol SD 200) and kollidon CL (1-
4K) or explotab (1-4E) were added as super disintegrants and compacted under low 
compression force. By an appropriate combination of excipients it was thus possible 
to obtain orally disintegrating tablets and a delayed release of Ibuprofen using simple 
and conventional techniques. 
Jean Paul remon et al., 1997, formulated and produced rapidly disintegrating tablets 
by lyophilization using hydrochlorothiazide as a model drug. The influence of 
different formulation and process parameters on the characteristics of lyophilized oral 
dosage forms was investigated. Maltodextrins, gelatins, xanthin gum and hydroxy 
ethyl cellulose were evaluated as excipients in the formulation of freeze dried tablets. 
The resulting tablets were analyzed for mechanical strength, porosity, disintegration 
time and residual moisture. The strength of the tablets was enhanced by using higher 
maltodextrin concentrations. The incorporation of hydrochlorothiazide in the 
formulations induced a decrease in strength of the tablets. The percentage of HCT 
released within 10 minutes was 64.55±2.87% and 77.84±8.94% for the reference 
tablets and the lyophilized tablet formulation respectively. The addition of PEG 6000 
(1%w/v) resulted in an increase of drug release as 93.3% from the lyophilized tablets 
within 10 minutes, however the incorporation of PEG 6000 in the formulation 
resulted in a decrease in the strength of the tablets.     
 
CHAPTER II                                                                           LITERATURE REVIEW 
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	40	
 
Yoshiteru watanabe et al., 1997, developed new method of preparing high porosity, 
rapidly saliva soluble compressed tablets of meclizine using mannitol with camphor 
as subliming material compressed tablets of water soluble material, prepared using 
mannitol, did not rapidly dissolve in water since it is difficult for water to penetrate 
into the tablets due to their low porosity. To increase the porosity of the tablets which 
are prepared by direct compression using mannitol, they developed a novel method 
whereby camphor, a subliming material is removed by sublimation from compressed 
tablets prepared using a mixture of mannitol and camphor. A high porosity was 
achieved due to the formation of many pores where camphor particles previously 
existed in the compressed mannitol tablets prior to sublimation of the camphor. These 
compressed tablets which have high porosity (approximately 30%) rapidly dissolved 
within 15seconds in saliva using mannitol and camphor of meclizine (antidinic agent) 
tablet with high porosity which dissolves rapidly in saliva. 
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CHAPTER – III 
AIM OF THE WORK 
Hypertension is becoming an important public health challenge worldwide. 
Hypertension is one of the main risk factors for cardiovascular diseases, which is one 
of the leading causes of death in developed countries. The relationship between blood 
pressure and risk of cardiovascular disease is continuous, consistent and independent 
of other risks. 
The higher the blood pressure, the greater is the chance of ischemic heart 
disease, stroke, heart failure and kidney diseases. Therefore prevention, detection, 
treatment and control of hypertension should receive high priority.  
In the treatment of hypertension, the patient's persistence to therapeutic 
regimen is very important. The patient should follow the regimen sincerely and 
should not skip the doses. The most common reasons for noncompliance or non-
persistence to antihypertensive therapy are dysphagia (difficulty in swallowing seen 
in nearly 50% of general population) and during travelling due to non-availability of 
water to take medication. 
Fast onset of action is a major concern in the treatment of hypertension. As 
the patients with sudden increased blood pressure, there is a marked reduction in 
functional ability and extreme restlessness. To overcome these problems concept of a 
patient-friendly tablet i.e. fast-dissolving tablet (FDT) has emerged. Fast dissolving 
tablets (FDTs) are solid single unit dosage forms that are placed in mouth, allowed to 
disperse/ dissolve in the saliva without the need of water and provide a quick onset of 
action. Some drugs are absorbed from mouth, pharynx and esophagus as the saliva 
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passes down into the stomach. FDTs disintegrate or dissolve in mouth in less than a 
minute, so there is no need to swallow the tablet or no need of water to take it. 
Torsemide is a pyridine sulfonyl urea type loop diuretic indicated for the 
treatment of hypertension and edema in congestive heart failure. It may be used alone 
or in combination with thiazide diuretics. It inhibits reabsorption of sodium and 
chloride in the ascending loop of henle and distal renal tubule, interfering with the 
chloride-binding co-transport system, thus causing increased excretion of water, 
sodium, chloride, magnesium and calcium. It does not alter glomerular filtration rate, 
renal plasma flow, or acid-base balance. The drug is absorbed with little first-pass 
metabolism, and the serum concentration reaches its peak (Cmax) within 1 hour after 
oral administration. The drug has a biologic half life of about 3.5hour.  
Conventional torsemide tablets available in market are not suitable where 
quick onset of action is required. To overcome the drawbacks development of FDTs 
of torsemide improves the patient compliance. 
The aim of present work is to prepare fast dissolving tablets of torsemide 
using super disintegrants (sodium starch glycolate, crospovidone, croscarmellose 
sodium). The best formulation selection is on the basis of release pattern, 
disintegration time, wetting time and water absorption ratio. 
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CHAPTER – IV 
PLAN OF WORK 
1. PREPARATION OF STANDARD CALIBRATION CURVE 
               a) Determination of λ max 
               b) Preparation of calibration curve     
2. PREFORMULATION (COMPATIBILITY STUDIES) 
               a) Infrared spectroscopic studies 
3. PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
               a) Angle of repose 
               b) Bulk density 
               c) Tapped density 
               d) Carr’s index 
               e) Hausner’s ratio 
               f) Drug content for powder blend 
4. PREPARATION OF FAST DISSOLVING TABLETS (DIRECT 
COMPRESSION METHOD) 
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5. POST COMPRESSIONAL EVALUATION OF FAST DISSOLVING 
TABLETS 
               a) General appearance 
               b) Thickness and Diameter 
               c) Hardness 
               d) Weight variation 
               e) Friability test 
               f) Drug content 
               g) Wetting time 
               h) Water absorption ratio 
    i) In-vitro disintegration test 
               j) In-vitro dissolution test 
6. SELECTION AND EVALUATION OF BEST FORMULATION 
               a) Infrared spectroscopic studies for best formulation 
               b) Differential scanning colorimetric (DSC) studies for best formulation 
               c)  X-ray diffraction studies for best formulation 
               d) Stability studies. 
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CHAPTER – V 
MATERIALS AND EQUIPMENTS 
 
 
 
 
 
 
 
MATERIALS DISTRIBUTORS 
Torsemide Micro labs (P) Ltd, Hosur. 
Sodium starch glycolate Pharmafabrikon, Madurai. 
Croscarmellose sodium Pharmafabrikon, Madurai. 
Crospovidone Pharmafabrikon, Madurai. 
Mannitol Nice Chemicals, Cochin. 
Microcrystalline cellulose Central Drug House (P) Ltd, New 
Delhi, India. 
Sodium lauryl sulphate Rankem Fertilizers &Chemicals Ltd, 
New Delhi, India.  
Sodium saccharin Central Drug House (P) Ltd, New 
Delhi, India. 
Peppermint  flavor Central Drug House (P) Ltd, New 
Delhi, India. 
Talc Nice chemicals, Cochin. 
Magnesium stearate Nice chemicals, Cochin. 
0.1N HCl Spectrum Reagents &Chemicals (P) 
Ltd, Edayar, Cochin. 
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EQUIPMENTS SUPPLIERS 
Electronic Weighing Balance A&D Company, Japan. 
Single punch tablet compression machine Cad mach Machinery Co. Pvt, 
Ahmadabad. 
UV Visible spectrophotometer Shimazdu UV-1700, Japan. 
Digital tablet dissolution test apparatus  Lab India Disso apparatus 2000, India. 
Friability test apparatus Indian Equipment corporation, 
Mumbai. 
Tablet hardness tester Praveen Enterprises, Bangalore. 
Vernier caliper Linker, Mumbai. 
Disintegration  test apparatus Rolex, India. 
Fourier transform infrared spectroscopy Shimadzu, Japan. 
Differential  scanning colorimeter DSC Q200 V24.4 Instrument, USA. 
Powder X-ray diffractometer XD, Shimadzu, Japan. 
Scanning electron microscopy Hitachi X650, Tokyo, Japan 
Environmental Chamber In lab   Equipments (P) Ltd, Madras. 
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CHAPTER – VI 
DRUG PROFILE 
Drug name 
Torasemide 
Synonyms 
 Torasemidum (Latin) 
 Torasemida (Spanish) 
Categories 
 Anti hypertensive agents 
 Diuretics 
Structural Formula 
 
Chemical name 
1-{4-[(3 methyl phenyl) amino] pyridine -3- sulfonyl}-3- (propan -2-yl) urea. 
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Molecular formula 
C16H20N4O3S 
Description 
Nature  :  White to off white crystalline powder. 
Solubility : Slightly soluble in water. The predicted log P value of               
                          torsemide is 1.76. But it is soluble in methanol (2mg/ml) and     
                          0.1N HCl.                                                                                                            
Melting Point :  164°C 
pKa                  :  7.1                                                                                                                      
Molecular weight 
348.43 gm/ml 
Mechanism of Action: 
It inhibits reabsorption of sodium and chloride in the ascending loop of henle 
and distal renal tubule, interfering with the chloride-binding co-transport system, thus 
causing increased excretion of water, sodium, chloride, magnesium and calcium. It 
does not alter glomerular filtration rate, renal plasma flow, or acid-base balance. 
Pharmacokinetics 
Absorption 
Bioavailability is approximately 80% 
Volume of distribution  
The volume of distribution of torsemide is 12 liters to 15 liters in normal 
adults or in patients with mild to moderate renal failure or congestive heart failure. In 
patients with hepatic cirrhosis, the volume of distribution is approximately doubled. 
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Protein binding 
>99%.  
Metabolism  
Hepatic metabolism accounts for approximately 80% of total clearance. 
Carboxylic acid derivative, the major metabolite, is inactive. 
Route of elimination 
Torsemide is cleared from the circulation by both hepatic metabolism 
(approximately 80% of total clearance) and excretion into the urine (approximately 
20% of total clearance in patients with normal renal function). 
Half Life 
Approximately 3.5 hours.  
Indications 
 Treatment of hypertension alone or in combination with other 
antihypertensive agents. 
 Treatment of edema associated with congestive heart failure, renal disease, or 
hepatic disease. 
Dosage and administration: 
Hypertension 
The usual oral initial dose is 5 mg once daily. If the 5 mg dose does not 
provide adequate reduction in blood pressure within 4 to 6 weeks, the dose may be 
increased to 10 mg once daily. If the response to 10 mg is insufficient, an additional 
antihypertensive agent should be added to the treatment regimen. 
Hepatic Cirrhosis 
The usual initial dose is 5 mg or 10 mg of once-daily oral or IV torsemide, 
administered together with an aldosterone antagonist or a potassium-sparing diuretic. 
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If the diuretic response is inadequate, the dose should be titrated upward by 
approximately doubling until the desired diuretic response is obtained. Single doses 
higher than 40 mg have not been adequately studied. 
Congestive Heart Failure 
The usual initial dose is 10 mg or 20 mg of once - daily oral or intravenous. If 
the diuretic response is inadequate, the dose should be titrated upward by 
approximately doubling until the desired diuretic response is obtained. Single doses 
higher than 200 mg have not been adequately studied. 
Overdosage 
 Symptoms include electrolyte depletion, volume depletion, hypotension, 
dehydration, and circulatory collapse. 
 Electrolyte depletion may manifest as weakness, dizziness, mental confusion, 
anorexia, lethargy, vomiting, and cramps. 
Side effects of Torsemide: 
The common side effects of torsemide are constipation; dizziness or light 
headedness when sitting up or standing; excessive urination; headache; increased 
cough; nasal inflammation; nausea. Seeking medical attention right away should be 
done if any of these SEVERE side effects occur: Severe allergic reactions (rash; 
hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, 
lips, or tongue); chest pain; diarrhea; dry mouth or unusual thirst; hearing loss or 
ringing in the ears; loss of appetite; muscle pain or cramps; rapid or irregular 
heartbeat; rectal bleeding; restlessness; unusual tiredness or weakness; vomiting. 
Drug Interactions 
 Coadministration of torsemide was associated with significant reduction in the 
renal clearance of spironolactone, with corresponding increases in the AUC. 
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However, clinical experience indicates that dosage adjustment of either agent 
is not required. 
 Because torsemide and salicylates compete for secretion by renal tubules, 
patients receiving high doses of salicylates may experience salicylate toxicity 
when torsemide is concomitantly administered. 
 The natriuretic effect of torsemide (like that of many other diuretics) is 
partially inhibited by the concomitant administration of indomethacin. This 
effect has been demonstrated for torsemide under conditions of dietary sodium 
restriction (50 mEq/day) but not in the presence of normal sodium intake (150 
mEq/day). 
 Coadministration of probenecid reduces secretion of torsemide into the 
proximal tubule and thereby decreases the diuretic activity of torsemide. 
 Other diuretics are known to reduce the renal clearance of lithium, inducing a 
high risk of lithium toxicity, so coadministration of lithium and diuretics 
should be undertaken with great caution, if at all. Coadministration of lithium 
and torsemide has not been studied. 
 Other diuretics have been reported to increase the ototoxic potential of 
aminoglycoside antibiotics and of ethacrynic acid, especially in the presence 
of impaired renal function. These potential interactions with torsemide have 
not been studied. 
Contraindications 
 Allergy to torsemide 
 Electrolyte depletion 
 Anuria 
 Renal failure 
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 Hepatic coma 
 Gout 
 Diabetes mellitus 
 Lactation 
 
(US Pharmacopoeia, page no-382,  
www.drugs.com, www.usfda.com and www.drugbank.com) 
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CHAPTER – VII 
EXCIPIENT PROFILE 
CROSPOVIDONE 
Synonyms: 
 Cross linked Povidone. 
  Kollidon. 
  Polyplasdone. 
  Polyvinylpoly pyrrolidone. 
  1-vinyl-2-pyrrolidinone homopolymer. 
Chemical Name: 
                  1-Ethenyl-2-pyrrolidinone homopolymer.  
Chemical Structure: 
 
Empirical formula: 
             (C6H9NO) n  
Molecular Weight:   
 >1 000 000 
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Functional category: 
Tablet disintegrant. 
 Application in Pharmaceutical formulation: 
 Tablet disintegrant and dissolution agent.  
 Solubility enhancer for poorly soluble drug. 
Description: 
Crospovidone is a white to creamy-white, finely divided, free flowing, 
practically tasteless, odorless or nearly odourless, hygroscopic powder. 
Stability and storage condition: 
Crospovidone is hygroscopic; it should be stored in an airtight container in a 
cool, dry place. 
 Incompatibilities: 
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular 
adduct with some materials. 
 Handling Precautions: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection, gloves, and a dust mask are recommended (Hand 
book of Pharmaceutical excipients by Raymond C Rowe -5th edition, 214-216). 
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CROSCARMELLOSE SODIUM 
Synonyms: 
 Ac-Di-Sol. 
 Cross linked carboxymethylcellulose sodium. 
 Explocel. 
 Modified cellulose gum. 
 Primellose. 
 Solutab. 
 Vivasol. 
Chemical Name: 
Cross linked carboxy methyl ether Cellulose sodium salt.  
Functional Category: 
Tablet and capsule disintegrant. 
Applications in Pharmaceutical Formulation: 
 Disintegrating agent for tablets and capsules. 
Description: 
 White or grayish white powder. 
 Odourless and tasteless. 
 Insoluble in water. Practically insoluble in acetone, ethanol and toluene. 
Pharmacopoeial Specifications: 
 pH (1% w/v dispersion) 5.0–7.0 
 Loss on drying ൑10% 
 Heavy metals ൑10 ppm 
 Sodium chloride and sodium glycolate	൑ 0.5% 
 Sulfated ash 14.0–28.0% 
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 Settling volume 10.0–30.0 ml 
 Acidity/alkalinity: pH = 5.0–7.0 in aqueous dispersions. 
 Density (bulk): 0.529 g/cm3  
 Density (tapped): 0.819 g/cm3  
 Density (true): 1.543 g/cm3  
Stability and Storage Conditions: 
Croscarmellose sodium should be stored in a well-closed container in a cool, 
dry place. 
Incompatibilities: 
 Croscarmellose sodium is not compatible with strong acids or with soluble 
salts of iron and some other metals such as aluminum, mercury, and zinc. 
Handling Precautions: 
 Croscarmellose sodium may be irritant to the eyes; eye protection is 
recommended. (Hand book of Pharmaceutical excipients by Raymond C Rowe -5th 
edition, 211-213). 
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SODIUM STARCH GLYCOLATE 
Synonyms: 
 Explosol. 
 Explotab. 
 Primojel. 
 Starch carboxymethyl ether, sodium salt. 
 Tablo. 
 Vivastar P. 
Chemical Name: 
Sodium carboxymethyl starch. 
Chemical structure: 
 
Functional Category: 
Tablet and capsule disintegrant. 
Application in Pharmaceutical Formulation: 
 Sodium starch glycolate is used as a disintegrant in capsule and tablet 
formulations. 
 Sodium starch glycolate is also used as a suspending vehicle. 
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Description 
 Sodium starch glycolate is a white to off-white, odorless, tasteless, free 
flowing powder 
 It does not melt, but chars at approximately 200oC 
 It is sparingly soluble in ethanol (95%) but practically insoluble in water. 
Pharmacopoeial Specifications: 
 Specific surface area: 0.24m2/g; 
 Swelling capacity: In water, sodium starch glycolate swells to up to 300 times 
its volume. 
 Viscosity (dynamic): 4200 mPa s (200 cP) for a 4% w/v aqueous dispersion. 
 Viscosity is 4.26 mPa s for a 2% w/v aqueous dispersion. 
Stability and Storage Conditions: 
 Sodium starch glycolate should be stored in a well-closed container in order 
to protect it from wide variations of humidity and temperature, which may cause 
caking. 
Incompatibilities: 
Sodium starch glycolate is incompatible with ascorbic acid. 
Handling Precautions: 
Sodium starch glycolate may be irritant to the eyes; eye protection and gloves 
are recommended. (Hand book of Pharmaceutical excipients by Raymond C Rowe -
5th edition). 
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SODIUM LAURYL SULFATE 
Synonyms: 
 Dodecyl sodium sulfate. 
 Elfan 240. 
 Texapon K12P.   
 Sodium dodecyl sulfate.   
 Sodium monododecyl sulfate. 
Chemical Name: 
Sulfuric acid monododecyl ester sodium salt. 
Chemical Structure: 
 
Empirical formula: 
C12H25NaO4S 
Molecular weight: 
288.38 
HLB value: 
≈ 40 
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Functional category: 
Anionic surfactant; detergent; emulsifying agent; skin penetrant; tablet and 
capsule lubricant; wetting agent. 
Application in pharmaceutical formulation and technology: 
Sodium lauryl sulfate is an anionic surfactant employed in a wide range of non 
parentral pharmaceutical formulations and cosmetics. 
Use Concentration (%) 
Anionic emulsifiers, forms self emulsifying bases 
with fatty alcohols 
0.5–2.5 
Detergent in medicated shampoos ≈10 
Skin cleanser in topical applications 1 
Solubilizer in concentrations greater than critical 
micelle concentration 
>0.0025 
Tablet lubricant 1.0–2.0 
Wetting agent in dentrifices 1.0–2.0 
                                                                
 It is a detergent and wetting agent effective in both alkaline and acidic 
conditions. 
 In recent years it has found application in analytical electrophoretic 
techniques;SDS (sodium dodecyl sulfate) polyacrylamide gel electrophoresisis 
one of the more widely used techniques for the analysis of proteins. 
 The sodium lauryl sulfate has been used to enhance the selectivity of micellar 
electrokinetic chromatography (MEKC). 
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Description: 
           SLS consists of white or cream to pale yellow- colored crystals, flakes, or 
powder having a smooth feel, a soapy. Bitter taste and a faint odour of fatty 
substances. 
Melting point: 
204-207°c (for pure substance) 
Solubility: 
Freely soluble in water, giving an opalescent solution; practically insoluble in 
chloroform and ether. 
Stability and storage condition: 
Sodium lauryl sulfate is stable under normal storage conditions. However, in 
solution, under extreme conditions i.e. PH 2.5 or below, it undergoes hydrolysis to 
lauryl alcohol and sodium bisulfate. 
            The bulk material should be stored in a well closed container away from 
strong oxidizing agents in a cool, dry place. 
Incompatibilities: 
Sodium lauryl sulfate reacts with cationic surfactants, causing loss of activity 
even in concentrations too low to cause precipitation. Unlike soaps, it is compatible 
with dilute acids and calcium and magnesium ions. Solutions of sodium lauryl sulfate 
(PH 9.5-10.0) are mildly corrosive to mild steel, copper, brass, bronze and aluminium. 
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Sodium lauryl sulfate is also in compatible with some alkaloidal salts and precipitates 
with lead and potassium. 
Handling precautions: 
 Observe normal precautions appropriate to the circumstances and quantity of 
material handled. 
 Inhalation and contact with the skin and eyes should be avoided; eye 
protection gloves, and other protective clothing, depending on the 
circumstances, are recommended. 
 Adequate ventilation should be provided or a dust respirator should be worn. 
Prolonged or repeated exposure should be avoided.  
 Sodium lauryl sulfate emits toxic fumes on combustion. (Hand book of 
Pharmaceutical excipients by Raymond C Rowe -5th edition, 1811- 1816). 
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Description: 
 Magnesium stearate is a very fine, light white powder. 
 Faint odour. 
 Characteristic taste. 
 Greasy to the touch and readily adheres to the skin.  
Pharmacopoeial Specifications: 
Freezing point 5538C 
Nickel 45 ppm 
Cadmium 43 ppm 
Loss on drying 46.0% 
Chloride 40.1% 
Sulfate 41.0% 
Lead 410 ppm 
 
Stability and Storage Conditions: 
           Magnesium stearate should be stored in a well closed container in a cool, dry 
place. 
Incompatibilities: 
Incompatible with strong acids, alkalis and iron salts. Avoid mixing with 
strong oxidizing materials. Magnesium stearate cannot be used in products containing 
aspirin, some vitamins, and most alkaloidal salts. 
Safety: 
Oral consumption of large quantities may produce a laxative effect or mucosal 
irritation. 
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Handling Precautions: 
 Eye protection and gloves are recommended. 
 Excessive inhalation of magnesium stearate dust may cause upper respiratory 
tract discomfort, coughing, and choking. (Hand book of Pharmaceutical 
excipients by Raymond C Rowe -5th edition, 430-433). 
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 Plasticizer in soft-gelatin capsules, as a component of sustained-release tablet 
formulation. 
 It is used as a carrier in dry powder inhalers. 
 It is also used as diluents in rapidly dispersing oral dosage forms. 
 It is used in food applications as a bulking agent. 
Description: 
 Mannitol is a white, odorless, crystalline powder, or free-flowing granules. 
 It has a sweet taste. 
 Microscopically, it appears as orthorhombic needles when crystallized from 
alcohol. 
 Mannitol shows polymorphism.  
Pharmacopoeial Specifications: 
 Density (bulk):0.430 g/cm3. 
 Density (tapped):0.734 g/cm3. 
 Density (true): 1.514 g/cm3. 
 Dissociation constant: pKa = 13.5 at 188C. 
 Flowability: powder is cohesive, granules are free flowing. 
 Melting point: 166–168oC. 
 Loss on drying:  40.3%. 
Stability and Storage Conditions: 
It should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
 Mannitol solutions, 20% w/v or stronger, may be salted out by potassium 
chloride or sodium chloride. 
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 Mannitol is incompatible with xylitol infusion and may form complexes with 
some metals such as aluminum, copper, and iron. 
 Reducing sugar impurities in mannitol have been implicated in the oxidative 
degradation of a peptide in a lyophilized formation.  
Handling Precautions: 
Mannitol may be irritant to the eyes; eye protection is recommended. (Hand 
book of Pharmaceutical excipients by Raymond C Rowe -5th edition, 449-453). 
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MICROCRYSTALLINE CELLULOSE 
Synonyms: 
 Avicel PH. 
 Celex. 
 Celphere. 
 Ceolus KG. 
 Ethispheres. 
 Fibrocel. 
 Pharmacel. . 
 Vivapur. 
Chemical Name: 
Cellulose. 
Empirical Formula: 
(C6H10O5) n  
Molecular Weight: 
36 000 
Functional Category: 
 Adsorbent. 
 Suspending agent, Tablet and capsule diluents, tablet disintegrant. 
Application in Pharmaceutical Formulation: 
 Microcrystalline cellulose is used as a binder/diluent in oral tablet and capsule 
formulations.  
 Microcrystalline cellulose is used as a lubricant and disintegrant agent in tablet 
formulation. 
 Microcrystalline cellulose is also used in cosmetics and food products.  
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Description: 
Microcrystalline cellulose is a white, odorless, tasteless, crystalline powder 
composed of porous particles.  
Use Concentration (%) 
 Adsorbent: 20–90 
 Antiadherent: 5–20 
 Capsule binder/diluent: 20–90 
 Tablet disintegrant : 5–15 
 Tablet binder/diluents: 20–90 
Pharmacopoeial Specifications: 
 pH: 5.0–7.0  
 Loss on drying: 47.0%  
 Residue on ignition: 40.05% 
 Sulfated ash: 40.1% 
 Heavy metals: 410 ppm  
Typical Properties: 
 Density (tapped):0.478 g/cm3, 
 Density (true): 1.512–1.668 g/cm3 
 Flowability: 1.41 g/s for Emcocel 90M. 
 Melting point: chars at 260–2708C. 
 Microcrystalline cellulose is hygroscopic. 
Stability and Storage Conditions: 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities: 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
Handling Precautions: 
 Microcrystalline cellulose may be irritant to the eyes. Gloves, eye protection, and a 
dust mask are recommended. (Hand book of Pharmaceutical excipients by Raymond 
C Rowe -5th edition132-135). 
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SACCHARIN SODIUM 
Synonyms: 
1,2-Benzisothiazolin-3-one 1,1-dioxide, sodium salt; Crystallose E954; 
sodium o-benzosulfimide; soluble gluside; soluble saccharin; sucaryl sodium. 
Chemical Name: 
1, 2-Benzisothiazol-3(2H)-one 1, 1-dioxide, sodium salt for the dehydrate for 
the anhydrous material. 
Chemical structure: 
 
Empirical Formula: 
C7H4NNaO3S  
Molecular Weight: 
205.16 
Functional Category: 
Sweetening agent. 
Application in Pharmaceutical Formulation: 
Saccharin sodium is an intense sweetening agent used in beverages, food 
products, table-top sweeteners and pharmaceutical formulations such as tablets, 
powders, medicated confectionery, gels, suspensions, liquids, and mouthwashes; It is 
also used in vitamin preparations. 
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Uses of saccharin sodium: 
 Dental paste/gel 0.12–0.3% 
 IM/IV injections 0.9% 
 Oral solution 0.075–0.6% 
Description: 
Saccharin sodium occurs as a white, odorless or faintly aromatic, efflorescent, 
crystalline powder. It has an intensely sweet taste, with a metallic after taste that at 
normal levels of use can be detected by approximately 25% of the population. 
Saccharin sodium can contain variable amounts of water. 
Pharmacopoeial Specification: 
 Water 415.0%  
 Arsenic 42 ppm 
 Selenium 40.003% 
 Heavy metals 420 ppm  
 Assay (anhydrous basis) 99.0–101.0%  
Typical Properties: 
 Acidity/alkalinity: pH = 6.6 (10% w/v aqueous solution) 
 Density (bulk):0.8–1.1 g/cm3  
 Density (particle): 1.70 g/cm3 
 Density (tapped): 0.9–1.2 g/cm3  
 Moisture content: 14.5% w/w water 
 Solvent Solubility at 208C 
 Specific surface area: 0.25m2/g 
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Stability and Storage Conditions: 
              Saccharin sodium is stable under the normal range of conditions employed in 
formulations. Saccharin sodium should be stored in a well-closed container in a cool, 
dry place. 
Handling Precautions: 
               Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection and a dust mask are recommended. (Hand book of 
Pharmaceutican excipients by Raymond C Rowe -5th edition). 
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TALC 
Synonyms: 
Altalc, E553b, hydrous magnesium calcium silicate, hydrous magnesium 
silicate, Luzenac Pharma, magnesium hydrogen metasilicate, Magsil Osmanthus, 
Magsil Star, powdered talc, purified French chalk, Purtalc, soapstone, steatite, 
Superiore. 
Chemical Name: 
Talc  
Empirical Formula: 
 Mg6(Si2O5)4(OH)4. 
Chemical Structure: 
 
Functional Category: 
Anticaking agent, glidant, tablet and capsule diluent, tablet and capsule 
lubricant. 
Applications in Pharmaceutical Formulations: 
 Lubricant and diluents. 
 Dissolution retardant in the development of controlled-release products. 
 An adsorbant. 
 Dusting powder. 
 
CHAPTER VII                                                                           EXCIPIENT PROFILE	
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	76	
 
 Talc is additionally used to clarify liquids and is also used in cosmetics and 
food products, mainly for its lubricant properties. 
 Dusting powder: 90.0–99.0% 
 Glidant and tablet lubricant: 1.0–10.0% 
 Tablet and capsule diluents: 5.0–30.0% 
Description: 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
Pharmacopoeial Specifications: 
 Acidity/alkalinity: pH = 7–10 for a 20% w/v aqueous dispersion. 
 Hardness (Mohs): 1.0–1.5 
 Solubility: practically insoluble in dilute acids and alkalis, organic solvents, 
and water. 
 Specific gravity: 2.7–2.8 
 Specific surface area: 2.41–2.42m2/g 
Stability and Storage Conditions: 
Talc is a stable material and may be sterilized by heating at 1608C for not less 
than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation.Talc should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
Incompatible with quaternary ammonium compounds. 
Handling Precautions: 
Talc is irritant if inhaled and prolonged excessive exposure may cause 
pneumoconiosis. In the UK, the occupational exposure limit for talc is 1 mg/m3 of 
 
CHAPTER VII                                                                           EXCIPIENT PROFILE	
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	77	
 
respirable dust long-term (8-hour TWA).Eye protection, gloves, and a respirator are 
recommended. (Handbook of Pharmaceutical excipients by Raymond C Rowe - 5th 
edition, 641-643). 
CHAPTER VIII 
 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL DETAILS 
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CHAPTER – VIII 
EXPERIMENTAL DETAILS 
1. PREPARATION OF STANDARD CALIBRATION CURVE 
a) Determination of λ max 
    Preparation of 0.1N Hydrochloric Acid: 
A known volume of 8.5ml Hydrochloric acid is dissolved in distilled water 
and the volume is made upto 1 litre (USP 21st Revision, NF 16th Edition page no: 
1430). 
A known weight (100mg) of drug (Torsemide) is dissolved and diluted to 
100ml using 0.1N HCl to form a primary stock solution (1000µg/ml). The stock 
solution is further diluted using 0.1N HCl solution to 10µg/ml concentration. The 
resultant solution is scanned in the range of (200 – 400nm) by ultra visible 
spectrophotometer to get absorption maximum (λmax) (Rajesh Shukla et al., 2012). 
b) Preparation of calibration curve 
From the above prepared stock solution, different concentration (1 to 
10µg/ml) solutions are prepared using 0.1N HCl solution. The absorbances of these 
solutions are measured at λmax (288nm) by UV- spectrophotometer. A standard curve 
is plotted using concentration on X-axis and the absorbance obtained on Y-axis 
(Nilesh Jain et al., 2010). 
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2. PREFORMULATION (COMPATIBILITY STUDIES) 
a) Infrared spectroscopic studies 
The FTIR spectrum of pure drug and excipients are recorded on an Infrared 
spectrometer (Shimadzu, Japan) using KBr discs. The spectrum ranges 4000 to 400 
cm-1 (Songa Ambedkar Sunil et al., 2011). 
3. PRECOMPRESSIONAL EVALUATION OF POWDER BLEND  
a) Angle of repose (θ) 
Angle of repose is determined using fixed funnel method. The blend is poured 
through a funnel that can be raised vertically until a maximum cone height (h) is 
obtained. Radius of the heap(r) is measured and angle of repose is calculated using 
formula (Manish R. Bhise et al., 2013 and Aulton M.E., 2002) 
θ = tan-1 (h/r) 
Where, 
          θ = angle of repose, 
           h = height of pile, 
           r = radius of the base pile.  
The relationship between the angle of repose and powder flow is as follow in 
the table: 
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Table 1: Limits for angle of repose 
ANGLE OF REPOSE POWDER FLOW 
< 25o Excellent 
25-30 o Good 
30-40o Passable 
>40o Very poor 
 
b) Bulk density 
Apparent bulk density (LBD) is determined by pouring blend into a graduated 
cylinder .The bulk volume (vo) and weight of powder (m) is determined. The bulk 
density is calculated using the formula (Bhingare C.L et al., 2013) 
                                                    Weight of the powder (m)                                    
                                      LBD =   
                                                    Volume of the packing (vo) 
 c) Tapped density 
The measuring cylinder containing known mass of blend is tapped for a fixed 
time. The minimum volume (vt) occupied in the cylinder and weight of powder blend 
(m) as measured. The tapped density (TBD) is calculated using the formula (Dinesh 
Mohan S.et al., 2010) 
                                                             Weight of the powder (m)  
                                          TBD = 
                                                       Tapped volume of the packing (v t)  
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d) Carr’s index (I) 
The simplex way of measurement of the free flow of powder is 
compressibility, an indication of the ease with which a material can be induced to 
flow is given by compressibility index of the granules is determined by carr’s 
compressibility index (c) which is calculated by using the following formula 
(Devendra Revanand Rane et al., 2012) 
                                                                                                    
                                              C =    100X
TBD
)]LBDTBD[(                                                                        
e) Hausner’s ratio 
 Hausner ratio is an indirect index of ease of powder flow. It is calculated by 
the following formula  
                                                                           
                         Hausner ratio =   
)LBD(densityBulk
)TBD(densityTapped                        
                                                         
Where TBD is tapped density and LBD is bulk density. Lower hausner ratios 
(<1.25) indicate better flow properties than higher ones (>1.25) (Devandra Revanand 
Rane et al., 2012). 
f) Drug content for powder blend 
The Powder blend containing 5 mg equivalent of drug weighed, dissolved and 
volume is made upto 100ml with 0.1N HCl solution. From the above solution, 5 ml is 
taken and diluted with 0.1N HCl to obtain (10μg/ml) concentration. The absorbance 
of resulting solution is measured at 288nm using UV spectrophotometer (shimadzu 
UV-1700 pharma spec, Japan) and the drug content is estimated (Abdul Hasan Sathali 
A.et al., 2012 and Ganeshan et al., 2012). 
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4. PREPARATION OF FAST DISSOLVING TABLETS (DIRECT 
COMPRESSION METHOD) 
Different tablet formulations are prepared by direct compression technique. 
Drug, diluents, super disintegrants, surfactant and sweetener are passed through 
sieve#40. Magnesium stearate is passed through #80 sieve. Required quantity of drug 
and surfactant is mixed first than other excipients are mixed thoroughly. The resultant 
powder is compressed using cadmach compression machine equipped with 6mm flat 
punches by direct compression technique (Jain et al., 2011 and Biraju Patel et al., 
2009). 
5. POST COMPRESSIONAL EVALUATION OF FAST DISSOLVING 
TABLETS 
a) General appearance 
Five tablets from different batches are randomly selected and organoleptic 
properties such as colour, odour, taste, shape are evaluated (Ravi Kumar Nayak et al., 
2011). 
b) Thickness and Diameter 
 Thickness of tablet is determined using vernier caliper (Linker, Mumbai). 
Three tablets from each batch are used and an average value is calculated (Deepak 
Sharma et al., 2013 and Mahanthesha M.K. et al., 2013). 
c) Hardness  
 The tablet hardness, which is the force required to break a tablet in a diametric 
compression force. The hardness tester used in the study is Monsanto hardness tester, 
 
CHAPTER VIII                                                               EXPERIMENTAL DETAILS 
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	83	
 
which applies force to the tablet diametrically with the help of an inbuilt spring and 
expressed in kg/cm2 (Kautikwar P.S et al., 2009). 
d) Weight variation 
 Weight variation test is done with 20 tablets. It is the individual variation of 
tablet weight from the average weight of 20 tablets (Deepak Sharma et al., 2013 and 
Indian Pharmacopoeia 2010) 
Table 2: Limits for weight variation 
Average weight of tablet (mg) %  Deviation 
80mg or less ± 10 
More than 80 mg but less than 250 mg ± 7.5 
250 mg or more ± 5 
 
e) Friability test 
 The friability of tablets is measured using Roche friabilator. Tablets are 
rotated at 25 rpm for 4 minutes or upto 100 revolutions. The tablets are then 
reweighed after removal of fines and the percentage of weight loss is calculated 
(Kautikwar P.S et al., 2009 and Anas Bahnassi et al., 2012) 
                                                         (Initial weight-final weight)                                   
                                  % friability =                                                × 100 
                                                                   Initial weight 
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f) Drug content 
 The tablet is randomly selected from each batch, weighed individually and 
powdered. The powder equivalent to 5mg of torsemide are weighed and dissolved in 
100 ml of 0.1N HCl solution to obtain the stock solution. From the stock solution 
suitable dilution are prepared and analysed using UV- spectrophotometer at 288nm 
(Bhingare C.L et al., 2013). 
g) Wetting time 
 The wetting time of the tablets is measured using a very simple process. Five 
circular tissue paper of 10cm diameter are placed in a petri dish with a 10cm 
diameter. Ten milliliters of water containing a water soluble dye (eosin) is added to 
the petri dish. A tablet is carefully placed on the surface of tissue paper. The time 
required for water to reach the upper surface of the tablet is noted as the wetting time 
(Bhanushali akash k et al., 2011). 
h) Water absorption ratio 
 A piece of tissue paper folded twice is placed in a small petridish containing 
6ml of water. A tablet is put on the tissue paper and allowed to completely wet. The 
wetted tablet is then weighed. Water absorption ratio, R is determined using 
following equation   
                                                                                                                
                                                   R =  100x
Wa
WbWa                 
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Where, 
           Wa =Weight of tablet after water absorption  
           Wb= Weight of tablet before water absorption 
i) In-vitro disintegration test 
Disintegration is defined as “state in which no residue of the tablet or capsule 
remains on the screen of the apparatus”. The in vitro disintegration time is determined 
using disintegration test apparatus (Lab India Disso apparatus 2000, India). A tablet is 
placed in each of six tubes in the apparatus and a disc is added to each tube. Suspend 
the basket rack in the beaker containing 900 ml of distilled water at 370 C and move 
the basket containing tablets up and down through a distance of 5-6 cm at a frequency 
of 28-32 cycles per minute. The time in seconds taken for complete disintegration of 
the tablet with no discernible mass remaining in the apparatus are measured (Indian 
Pharmacopoeia., 1996. Page no: A-80 to A-81 and Hasan Mahmud Reza et al., 2012). 
Disintegration time 
a) Uncoated tablets:  5- 30 minutes 
b) Coated tablets:  1-2 hours 
c) Fast Dissolving tablets: less than 3 minutes (European Pharmacopoeia) 
j) In-vitro dissolution test 
The release rate of torsemide from fast dissolving tablets is determined using 
USP dissolution test apparatus II (paddle type). The dissolution test is performed 
using 900ml of 0.1N HCl at 37±0.50c and rotation speed of 50 rpm. A sample of 5ml 
solution is withdrawn from the dissolution apparatus every 5 minutes for 30 minutes 
after that 10 minutes time interval for next 30 minutes and the samples are replaced 
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with fresh dissolution medium. Absorbances of these solutions are measured at 288 
nm using UV spectrophotometer. Cumulative percentage drug release is calculated 
using an equation obtained from a standard curve (Shaikh RG et al., 2012 and 
Puttewar T.Y et al., 2010). 
6. SELECTION AND EVALUATION OF BEST FORMULATION 
a) Infrared spectroscopic studies for best formulation 
FDTs of torsemide (Best formulation) are subjected to infrared Spectroscopic 
studies as per the procedure already discussed in compatibility studies. 
b) Differential scanning colorimetric (DSC) studies for best formulation 
Differential scanning colorimetry is used for screening. The specified samples 
is hermetically sealed in a flat bottomed aluminium pans and heated in the differential 
scanning colorimeter (DSC Q200 V 24.4 Build 116) in an atmosphere of nitrogen and 
the rate of flow is 25ml/min. temperature range of 00 C to 2500 C is used and the 
heating rate is 100C/min (Preeti Karwa et al., 2013). 
The pure drug, excipients and final formulation (F27) are subjected to 
differential scanning colorimetry. 
c) X-ray diffraction studies for best formulation 
Powder X-ray diffraction pattern is traced employing X-ray diffractometer 
(XD, Shimadzu, Japan) for the samples, using Ni filtered CuK (α) radiation, a voltage 
of 45 kV, a current of 20 mA. The samples are analysed over 2θ range of 0-50 ° with 
scan step size of 0.0170° (2θ) and scan step time 20 s (Setia Anupama et al., 2011). 
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The pure drug, excipients and final formulation (F27) are subjected to X-ray 
diffraction study. 
d) Stability studies. 
Stability studies are carried out on optimized formulation. The tablets are 
RH for duration of two months. After an interval of two months samples are 
withdrawn and tested for various physical tests and drug release study (Uday S 
Rangole et al., 2008). 
                                        
CHAPTER IX 
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CHAPTER - IX 
RESULTS AND DISCUSSION 
1. PREPARATION OF STANDARD CALIBRATION CURVE 
a) Determination of λ max: 
Preparation of 0.1N Hydrochloric Acid: 
A known volume of 8.5ml Hydrochloric acid is dissolved in distilled water 
and the volume is made up to 1 litre (USP 21st Revision, NF 16th Edition page no: 
1430). 
The absorption maximum (λ max) of the torsemide was estimated by scanning 
the drug solution (10µg/ml) between 200-400 nm regions on UV spectrophotometer. 
The obtained spectrum showed that the absorption maximum (λ max) was 288nm in 
0.1N HCl which was shown in Figure 3(Rajesh Shukla et al., 2012 and Nilesh Jain et 
al., 2010). 
b) Preparation of calibration curve: 
A standard  calibration curve for the  drug  was  obtained  by  measuring  
absorbance of the solution (1-10μg/ml) at 288nm by plotting  the graph  of  
absorbance vs. concentration. The calibration plots of torsemide were shown in Table 
3 and Figure 4. The linear correlation co efficient was found to be γ= 0.9997. 
Torsemide obeys beer’s law within the concentration range of 1-10 µg/ml (Jain 
Deepthi et al., 2010 and Mishra Bibaswan et al., 2010). 
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2. PREFORMULATION (COMPATIBILITY) STUDIES 
a) Infrared Spectroscopic studies (IR): 
The Fourier Transform Infra Red Spectroscopy studies were carried out for 
pure drug, excipients and physical mixtures. The spectra were shown in Figure 5a, 
5b, 5c, 5d, 5e, 5f, 5g, 5h &5i. The spectral analysis of pure drug  showed the 
characteristics peaks at 3425 cm-1 , 3351.43 cm-1, 3051.49 cm-1, 1697.41 cm-
1,1464.98 cm-1, 1357.93 cm-1,1081.14 cm-1 ,899.82 cm-1. All the above characteristic 
peaks appear in the spectra of all samples were within the same wavelength number. 
This indicates that there were no interactions between the drug and physical mixture 
(Bhingare C.L et al., 2013). 
3. PRECOMPRESSION EVALUATION FOR POWDER BLEND 
a) Angle of repose (θ): 
The angle of repose was used to determine the flow properties of powder 
blend. The angle of repose of all the formulations ranged from 27°11’ to 36°69’. The 
results indicated that all the formulations exhibited good flow properties. The results 
of angle of repose for all the formulations were shown in Table 5A & 5B. 
b) Bulk density: 
The bulk density was used to determine the free flowing properties of powder 
blend.  The bulk density of all the formulations was in the range of 0.36 - 0.62 g/ml. 
The values of bulk density showed that the blend was not tightly packed and indicated 
good flow properties. The results of bulk density for all the formulations were shown 
in Table 5A & 5B. 
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c) Tapped density: 
The tapped density was used to access the free flowing properties of powder 
blend. Tapped density of all the formulations were in the range of 0.43 - 0.69 g/ml. 
The results indicated that the blends of all the formulation had good flow properties. 
The results of tapped density for all the formulations were shown in Table 5A & 5B. 
d) Carr’s index (I): 
The Carr’s compressibility index was used to access the free flowing 
properties of powder blend. The compressibility index of all the formulations ranged 
from 7.13% - 25.01%. This value below 15% indicates a powder having good flow 
property and good propensity of compression. The results of compressibility for all 
formulations were shown in Table 5A & 5B. 
e) Hausner’s ratio: 
The Hausner’s ratio was an indirect index of ease of powder flow. The 
Hausner’s ratio of all the formulations ranged from 1.07-1.33. It was less than 1.25 
indicated better flow property of blend. The results of Hausner’s ratio for all the 
formulations were shown in Table 5A & 5B. 
f) Drug content for powder blend: 
The drug content of the powder blends was used to ensure the therapeutic 
dosage of the active ingredient in the formulation. The drug content of all the 
formulations was in the range of 97.04% – 101.49%. The results indicated all the 
formulations were within the acceptable limits as per USP (USP Limit: not less than 
90% and not more than 110%). The results were shown in Table 5A & 5B. 
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4. PREPARATION OF FAST DISSOLVING TABLETS (DIRECT 
COMPRESSION METHOD) 
The fast dissolving tablet of torsemide was prepared by direct compression 
method using different ratio (2%, 4%, 6%, 8%, 10%, 12%, 14%, 16% and 18%) of 
superdisintegrants (sodium starch glycolate, croscarmellose sodium and 
crospovidone). The compositions of the different formulations were given in Table 
4A & 4B. 
Twenty eight formulations (F1-F28) were prepared. All the tablets were white 
colour and round in shape having 6 mm diameter. 
5. POST COMPRESSIONAL EVALUATION OF FAST DISSOLVING 
TABLETS 
The prepared tablets were evaluated on various parameters such as thickness, 
diameter, hardness, weight variation, friability, drug content, wetting time, water 
absorption ratio, in-vitro disintegration test and in-vitro dissolution test. The results 
were summarized in Table 6A & 6B.  
a) General appearance: 
The formulated tablets were white colour and round shaped. All tablets were 
elegant in appearance. The results were shown in Table 6A & 6B. 
b) Thickness and Diameter: 
The thickness and diameter of all the formulations were used to determine the 
uniformity of size and shape of the tablets. From the results it was found that the 
 
CHAPTER IX                                                               RESULTS AND DISCUSSION 
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	92	
 
thickness of the tablet in all formulation was 3.0mm- 3.2mm and the diameter of the 
tablet in all formulation was 6mm. The results indicating all the formulations had 
uniform size and shape. The results were shown in Table 6A & 6B. 
c) Hardness: 
The hardness of the tablets was used to determine the resistance capacity of 
the tablets to chipping, abrasion or breakage under conditions of storage, 
transportation and handling before usage. The hardness of the tablets of all the 
formulations was found to be 3-4 kg/cm2. The result indicated that all the tablets had a 
good mechanical strength. The results of the hardness for all the formulations were 
shown in Table 6A & 6B. 
d) Weight Variation Test: 
The weight variation test was used to ensure the uniformity of the tablet in all 
formulations. It was found that the entire tablets passes weight variation test, as the 
percentage weight variation was within the acceptable pharmacopoeia limits of 
±7.5%. The results were shown in Table 6A & 6B (Abhishek jain et al., 2011). 
e) Friability test: 
Friability test was measured to ensure the mechanical strength of tablet. The 
results showed that the friability of all the formulation was ranged from 0.27 % to 
0.83 %. Friability of all the formulation was lesser than 1 % which indicated the 
tablets had a good mechanical resistance. The results were shown in Table 6A & 6B 
(Bhanushali Akash .K et al., 2011).  
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f) Drug content: 
The drug content test was used to determine the uniform amount of active 
ingredient present in all formulations. The drug content in the content uniformity of 
all the formulations was found to be in the range of 97.58 % - 99.19 %. The results 
indicated all the formulations were within the acceptable limits as per USP (Limit: not 
less than 90% and not more than 110%). The results were shown in Table 6A & 6B. 
g) Wetting Time: 
Wetting time of the tablet was used to assess the capacity of the tablets to 
disintegrate by swelling of water. All the formulations showed quick wetting, this 
may be due to ability of swelling and also capacity of absorption of water. The results 
of wetting time of all the formulations were shown in Table 6A, 6B and Figure 7. 
The formulations  F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, 
F15, F16, F17, F18, F19, F20, F21, F22, F23, F24, F25, F26, F27, F28  showed the 
wetting time 118, 111, 102, 93, 79, 66, 52, 45, 34, 91, 82, 75, 68, 53, 47, 40, 31, 22, 
51, 44, 39, 33, 29, 25, 19, 13, 10, 251 seconds respectively. The results indicated that 
as the concentration of superdisintegrant increased wetting time was decreased. 
Formulation F27 containing Crospovidone (18%) shows lesser wetting time than 
other formulation. 
This may be due to fact that Crospovidone and Croscarmellose sodium 
perform their disintegrating action by wicking through capillary action and fibrous 
structure respectively with minimum gelling. Sodium starch glycolate is disintegrated 
by swelling mechanism leading to longer wetting time (Raghavendra Rao N.G et al., 
2010 and Abdul Hasan Sathali A. and Ganesan S. et al., 2012). 
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h) Water Absorption Ratio: 
The water absorption ratio test was used to ensure the capacity of the 
superdisintegrant to absorb the water. The results of water absorption ratio of all the 
formulation were shown in Table 6A & 6B. 
Formulations F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, 
F15, F16, F17, F18, F19, F20, F21, F22, F23, F24, F25, F26, F27, F28 showed the 
water absorption ratio 50.45%, 51.55%, 58.19%, 68.76%, 75.03%, 77.95%, 79.31%, 
80.12%, 83.10%, 27.69%, 41.39%, 50.09%, 50.58%, 55.67%, 58.86%, 61.02%, 
60.38%, 62.55%, 62.36%, 66.80%, 76.07%, 77.66%, 79.52%, 82.59%, 85.91%, 
89.52%, 91.90%, 23.30%. The results showed that, as concentration of super 
disintegrant increased water absorption ratio was also increased. Formulation F27 
containing Crospovidone shows highest water absorption ratio (91.90%) than other 
formulation. 
The reason for high water absorption ratio for Crospovidone may be due to 
highly porous structure, it draws large amount of water by water wicking mechanism 
into porous network of tablet resulting rapidly absorbs water into its network, and 
highest than formulation prepared with other superdisintegrants. It was indicated that 
water absorption ratio increased with decrease in wetting time (Arvind S.Singh et al., 
2010 and Abdul Hasan Sathali. A and Ganesan. S et al., 2012). 
i) In-vitro disintegration test: 
The In-vitro disintegration time was determined by disintegration test 
apparatus. Formulations F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, 
F15, F16, F17, F18, F19, F20, F21, F22, F23, F24, F25, F26, F27, F28 showed the  
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disintegration time 146, 145, 136, 124, 114, 107, 98, 94, 87, 127, 119, 115, 110, 94, 
87, 77, 82, 76, 94, 83, 74, 65, 71, 67, 64, 57, 53, 274 seconds respectively. It was 
observed that formulation F27 containing Crospovidone (18%) containing tablet 
disintegrate rapidly in a short time (53 seconds). The results of disintegration of all 
the tablets were found to be lesser than 3 minutes (European Pharmacopoeia, 2001) 
and so satisfied the criteria of fast dissolving tablets. The results were shown in Table 
6A, 6B and Figure 8. 
The faster disintegration time of Crospovidone tablets may be attributed to its 
rapid capillary activity and pronounced hydration with little tendency to gel 
formation. Thus these results suggest that the disintegration times can be decreased by 
using wicking type of disintegrants (Ajay Kumar Patil et al., 2011 and Abdul Hasan 
Sathali. A and Ganesan. S. et al., 2012).  
j) In-vitro dissolution test: 
The results of In-vitro drug release studies from fast dissolving tablets of 
torsemide were shown in the Table 7A, 7B, 7C, 7D, 7E, 7F & 7G.  
The results showed that the release profiles of different formulations varied 
according to the type of superdisintegrants and its percentage to the formulations. 
Maximum percentage of drug (More than 80%) was released from the all 
formulations within 10 minutes. 
Effect of Superdisintegrant on Drug Release: 
The formulations  F1, F2, F3, F4, F5, F6, F7, F8, F9  were prepared with 2%, 
4%, 6%, 8%, 10%, 12%, 14%, 16%, 18% sodium starch glycolate as a 
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superdisintegrant, showed the cumulative percentage of drug release 93.09%, 93.99%, 
92.17%, 90.90%, 90.53%, 88.55%, 96.34%, 91.99%, 95.09% respectively at 10 
minutes. Formulation F7 containing 14% sodium starch glycolate shows maximum 
drug release (96.34%) at 10 minutes. This result indicated that the optimum 
concentration of sodium starch glycolate was 14%. 
The formulation F10, F11, F12, F13, F14, F15, F16, F1, F18 were prepared 
with 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18% croscarmellose sodium as a 
superdisintegrant, showed the cumulative percentage of drug release 92.54%, 90.56%, 
94.00%, 84.75%, 88.20%, 92.73%, 84.91%, 91.27%, 86.54% respectively at 10 
minutes. Formulation F12 containing 6% croscarmellose sodium shows maximum 
drug release (94.00%) at 10 minutes. This result indicated that the optimum 
concentration of croscarmellose sodium was 6%. 
The formulation F19, F20, F21, F22, F23, F24, F25, F26, F27 were prepared 
with 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18% crospovidone as a 
superdisintegrant, showed the cumulative percentage of drug release 92.55%, 89.65%, 
92.74%, 90.00%, 89.10%, 90.01%, 95.98%, 93.81%, 99.62%  respectively at 10 
minutes. Formulation F27 containing 18% Crospovidone shows maximum drug 
release (99.62%) at 10 minutes.  This result indicated that the optimum concentration 
of crospovidone was 18%. 
The formulation F28 were prepared without superdisintegrant, showed the 
cumulative percentage of drug release of 22.36% at 10 minutes. 
From the results, the release rates of superdisintegrants were in the order: 
Crospovidone > Sodium starch glycolate > Croscarmellose sodium 
 
CHAPTER IX                                                               RESULTS AND DISCUSSION 
 
Fast dissolving tablets of Torsemide Reg. No. 261211304	 Page	97	
 
The maximum percentage of drug release was achieved by the formulation 
containing crospovidone (18%) as a superdisintegrant. It may be due to the results in 
the rapid disintegration of tablet in dissolution medium resulting in maximum drug 
release.  
Among twenty eight formulations, formulation 27 (F 27) was selected as a 
best formulation because of its lowest wetting time, disintegration time and highest 
water absorption ratio, drug release (Ravi Kumar Nayak et al., 2011). 
6) SELECTION AND EVALUATION OF BEST FORMULATION 
a) Infrared spectroscopic studies for best formulation: 
Infrared spectrum was performed for the fast dissolving tablets, the major 
peaks of the drug still shown in the spectrum at 3400.62 cm-1, 3348.54cm-1, 2968.55 
cm-1, 1654.01 cm-1, 1462.09 cm-1, 1315.5 cm-1, 1083.07cm-1, 881.5 cm-1 indicated that 
there was no interaction between the drug and final formulation in the preparation of 
fast dissolving tablets. The result was shown in Figure 5j. 
b) Differential scanning colorimetric (DSC) studies for best formulation: 
Any possible drug polymer interaction can be studied by thermal analysis. The 
DSC thermogram of torsemide was typical of a crystalline substance, exhibiting a 
sharp endothermic peak at 167.97o C corresponding to its melting and decomposition. 
The thermograms of the final formulation of torsemide with other excipients showed 
the existence of the drug endothermic peak which could indicate the absence of 
interactions between torsemide and other excipients. The DSC thermogram of pure 
drug and its final formulation is represented in Figure 6a, 6b, 6c, 6d, 6e, 6f and 6g 
(Ravi kumar nayak et al., 2011). 
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c) X-ray diffraction studies for best formulation: 
The PXRD graph of Torsemide, sodium starch glycolate, croscarmellose 
sodium, crospovidone, microcrystalline cellulose, sodium lauryl sulphate and best 
formulation (F27) were shown in Figure 11a, 11b, 11c, 11d, 11e, 11f and 11g. The 
PXRD spectra of torsemide show numerous distinct peaks for crystallinity at 2θ value 
of 6.13, 13.45, 17.63, 18.86, 20.88, 22.60, 23.55, 26.04, 28.11 and 28.65 indicating 
that torsemide present in the highly crystalline form. The major X-ray diffraction 
peaks of torsemide fast dissolving tablet formulation were suppressed or absent, 
indicating the decrease in the crystallinity of the torsemide. These results of PXRD 
were strongly supported by the above DSC observations (Sarita Jangra bhyan et al., 
2013). 
d) Stability studies: 
The stability studies were investigated whether the physical chemical 
parameters and dissolution of fast dissolving tablets is affected by storage under as  
40° C ± 2°C and  75%± 5% RH.  The best formulation of three batches is stored at 
40° C ± 2°C and  75%± 5% RH for two months.  The results showed no significant 
changes in physical appearance, hardness, thickness, drug content, wetting time, water 
absorption ratio, disintegration time and dissolution test of aged tablets compared to 
the fresh fast dissolving tablets. This indicates that the fast dissolving tablets were 
stable under these storage conditions. The results were shown in Table 8A, 8B and 
Figure 10. 
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TABLE 3: CALIBRATION OF TORSEMIDE IN 0.1N HCl 
    n=3*                                                                                    γ= 0.9997 
 
 
 
 
S.No 
 
Concentration(μg/ml) 
 
Absorbance ± SD* 
 
1. 1 0.033 ± 0.001 
2. 2 0.067 ± 0.002 
3. 3 0.100 ± 0.001 
4. 4 0.134 ± 0.002 
5. 5 0.166 ± 0.001 
6. 6 0.203 ± 0.002 
7. 7 0.232 ± 0.003 
8. 8 0.264 ± 0.002 
9. 9 0.301 ± 0.002 
10. 10 0.332 ± 0.002 
                                             TABLE 4A: FORMULATION OF FAST DISSOLVING TABLET OF TORSEMIDE 
 
Ingredients 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
 
F10 
 
F11 
 
F12 
 
F13 
 
F14 
 
F15 
 
F16 
 
F17 
 
F18 
 
Torsemide (mg) 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
Sodium starch 
glycolate (mg) 
 
2 
 
4 
 
6 
 
8 
 
10 
 
12 
 
14 
 
16 
 
18 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Croscarmellose 
sodium (mg) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
2 
 
4 
 
6 
 
8 
 
10 
 
12 
 
14 
 
16 
 
18 
Crospovidone 
(mg) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
Mannitol (mg) 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
Microcrystalline 
cellulose (mg) 
 
57.5 
 
55.5 
 
53.5
 
51.5
 
49.5
 
47.5
 
45.5
 
43.5
 
41.5
 
57.5 
 
55.5
 
53.5 
 
51.5 
 
49.5 
 
47.5 
 
45.5 
 
43.5 
 
41.5 
Sodium 
saccharin (mg) 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
Magnesium 
stearate (mg) 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
Talc (mg) 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
Peppermint 
flavour (mg) 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
Sodium lauryl 
sulphate (mg) 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
Total Weight 
(mg) 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
                                             TABLE 4B: FORMULATION OF FAST DISSOLVING TABLET OF TORSEMIDE 
 
Ingredients 
 
F19 
 
F20 
 
F21 
 
F22 
 
F23 
 
F24 
 
F25 
 
F26 
 
F27 
 
F28 
 
Torsemide (mg) 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
Sodium starch glycolate 
(mg) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Croscarmellose sodium 
(mg) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
Crospovidone (mg) 
 
2 
 
4 
 
6 
 
8 
 
10 
 
12 
 
14 
 
16 
 
18 
 
- 
 
Mannitol (mg) 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
Microcrystalline 
cellulose (mg) 
 
57.5 
 
55.5 
 
53.5 
 
51.5 
 
49.5 
 
47.5 
 
45.5 
 
43.5 
 
41.5 
 
59.5 
 
Sodium saccharin (mg) 
  
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
Magnesium stearate 
(mg) 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
Talc (mg) 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
Peppermint flavour 
(mg) 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
Sodium lauryl sulphate 
(mg) 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
Total Weight (mg) 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
TABLE 5A: EVALUATION OF MIXED POWDER BLEND OF TORSEMIDE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             n=3* 
 
Formulation 
code 
 
Angle of repose 
(°) ± SD* 
 
Bulk density 
(g/ml) ± SD* 
 
Tapped density 
(g/ml) ± SD* 
 
Carr’s index 
(%) ± SD* 
 
Hausner’s ratio 
± SD* 
 
Drug content 
(%)± SD* 
F1 31.58±4.27 0.42±0.00 0.52±0.00 20.01±0.05 1.24±0.00 95.70±1.20 
F2 32.39±3.16 0.46±.00 0.58±0.00 21.52±0.03 1.27±0.00 96.10±3.12 
F3 29.92±1.62 0.45±0.00 0.57±0.00 20.02±0.03 1.25±0.00 95.00±1.47 
F4 30.39±1.46 0.45±0.03 0.49±0.03 07.13±0.09 1.07±0.00 97.48±2.04 
F5 33.53±1.62 0.62±0.03 0.69±0.04 09.67±0.48 1.10±0.00 95.98±3.01 
F6 29.93±1.50 0.60±0.03 0.66±0.04 09.42±0.44 1.10±0.00 97.38±1.76 
F7 30.91±0.32 0.45±0.05 0.51±0.05 12.78±0.48 1.14±0.00 97.68±1.42 
F8 30.44±0.81 0.49±0.03 0.57±0.04 13.37±0.89 1.15±0.01 97.38±2.97 
F9 30.17±0.28 0.48±0.01 0.55±0.02 13.05±0.48 1.14±0.00 98.69±0.17 
F10 28.03±4.10 0.41±0.00 0.48±0.00 13.32±0.01 1.15±0.00 96.58±0.92 
F11 27.11±3.37 0.41±0.00 0.48±0.00 13.32±0.00 1.15±0.00 97.68±1.42 
F12 33.36±0.27 0.40±0.00 0.50±0.00 18.78±0.03 1.23±0.00 97.38±2.97 
F13 30.39±0.35 0.42±0.00 0.52±0.00 19.99±0.06 1.24±0.00 98.69±0.17 
F14 36.69±0.29 0.37±0.00 0.45±0.00 17.72±0.00 1.21±0.00 97.48±2.92 
TABLE 5B: EVALUATION OF MIXED POWDER BLEND OF TORSEMIDE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              n=3* 
 
Formulation 
code 
 
Angle of repose 
(°) ± SD* 
 
Bulk density 
(g/ml) ± SD* 
 
Tapped density 
(g/ml) ± SD* 
 
Carr’s index 
(%) ± SD* 
 
Hausner’s ratio 
± SD* 
 
Drug content 
(%)± SD* 
F15 30.73±0.50 0.36±0.00 0.43±0.00 16.70±0.00 1.20±0.00 95.77±4.13 
F16 30.42±0.49 0.43±0.01 0.50±0.01 13.05±0.49 1.14±0.00 97.48±2.92 
F17 30.23±0.67 0.44±0.03 0.51±0.04 13.37±0.90 1.15±0.01 98.19±0.30 
F18 30.59±0.32 0.45±0.03 0.52±0.04 13.33±0.94 1.15±0.01 98.48±1.08 
F19 30.60±0.44 0.41±0.00 0.55±0.00 25.01±0.06 1.33±0.00 97.58±1.20 
F20 31.30±0.40 0.39±0.00 0.47±0.00 17.69±0.10 1.21±0.00 98.19±0.30 
F21 30.33±0.57 0.39±0.01 0.47±0.02 18.00±0.64 1.21±0.01 98.08±1.13 
F22 30.33±0.13 0.41±0.02 0.48±0.02 14.86±3.39 1.17±0.04 97.98±1.14 
F23 30.33±0.32 0.41±0.01 0.48±0.02 14.58±3.60 1.17±0.05 97.98±1.48 
F24 30.56±0.34 0.37±0.00 0.44±0.01 15.68±3.38 1.18±0.04 97.98±0.75 
F25 30.95±0.27 0.45±0.03 0.49±0.03 07.13±0.09 1.07±0.00 98.59±1.05 
F26 30.33±0.28 0.62±0.03 0.69±0.04 09.67±0.48 1.10±0.00 96.98±0.30 
F27 30.98±0.46 0.60±0.03 0.66±0.04 09.42±0.44 1.10±0.00 99.19±0.62 
F28 30.64±0.54 0.42±0.01 0.47±0.02 12.77±0.48 1.14±0.00 96.58±0.92 
TABLE 6A: EVALUATION OF FAST DISSOLVING TABLETS 
  n=3* 
 
Formulation 
code 
 
General 
appearance 
Thickness 
(mm) 
Hardness 
(kg/cm2) 
Average 
weight   
(mg)±7.5 
Friability 
(%) 
Content 
uniformity 
(%) 
Disintegration 
time (sec) 
Water 
absorption 
ratio (%) 
Wetting 
time (sec) 
F1 White colour 3.2 3 99.20 0.83 98.39 146 50.45 118 
F2 White colour 3.1 3 95.88 0.34 99.19 145 51.55 111 
F3 White colour 3.1 3 98.16 0.58 98.79 136 58.19 102 
F4 White colour 3.0 3 97.67 0.51 98.59 124 68.76 93 
F5 White colour 3.2 3 98.36 0.41 98.39 114 75.03 79 
F6 White colour 3.0 4 98.18 0.53 98.19 107 77.95 66 
F7 White colour 3.1 3 98.70 0.41 97.88 98 79.31 52 
F8 White colour 3.1 3 98.72 0.36 97.58 94 80.12 45 
F9 White colour 3.1 3 98.48 0.35 98.09 87 83.1 34 
F10 White colour 3.1 3 98.40 0.4 97.99 127 27.69 91 
F11 White colour 3.2 3 98.79 0.43 97.98 119 41.39 82 
F12 White colour 3.2 3 98.44 0.56 98.29 115 50.09 75 
F13 White colour 3.1 4 98.44 0.32 98.08 110 50.58 68 
F14 White colour 3.2 3 98.79 0.27 98.59 94 55.67 53 
TABLE 6B: EVALUATION OF FAST DISSOLVING TABLETS 
Formulation 
code 
 
General 
appearance 
Thickness 
(mm) 
Hardness 
(kg/cm2) 
Average 
weight(mg)  
±7.5 
Friability 
(%) 
Content 
uniformity 
(%) 
Disintegration 
time (sec) 
Water 
absorption 
ratio (%) 
Wetting 
time (sec) 
F15 White colour 3.2 4 97.50 0.52 98.19 87 58.86 47 
F16 White colour 3.0 3 98.70 0.41 97.88 77 61.02 40 
F17 White colour 3.0 3       98.5 0.31 98.59 82 60.38 31 
F18 White colour 3.0 3 98.23 0.36 97.88 76 62.55 22 
F19 White colour 3.0 3 93.68 0.3 98.59 94 62.36 51 
F20 White colour 3.2 3 98.01 0.39 98.49 83 66.8 44 
F21 White colour 3.2 4 97.69 0.37 98.09 74 76.07 39 
F22 White colour 3.2 3 97.48 0.29 98.49 65 77.66 33 
F23 White colour 3.1 3 98.08 0.28 97.88 71 79.52 29 
F24 White colour 3.2 3 98.23 0.36 97.88 67 82.59 25 
F25 White colour 3.0 3 97.48 0.29 98.49 64 85.91 19 
F26 White colour 3.0 3 98.40 0.4 97.99 57 89.52 13 
F27 White colour 3.0 3 98.79 0.43 97.98 53 91.9 10 
F28 White colour 3.2 3 98.5 0.31 98.59 274 23.3 251 
  n=3*     
 TABLE 7A: IN VITRO RELEASE PROFILE OF TORSEMIDE FAST 
DISSOLVING TABLETS 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
F1 
 
F2 
 
F3 
 
F4 
 
5 62.04±0.54 61.32±0.31 59.51±0.31 57.89±0.31 
10 93.09±0.31 93.99±0.31 92.17±0.54 90.90±0.31 
15 89.91±0.31 93.25±0.54 90.15±0.31 89.78±0.31 
20 87.78±0.54 93.04±0.31 88.12±0.30 89.37±0.54 
25 88.26±0.54 92.82±0.31 87.16±0.54 89.14±0.31 
30 89.28±0.00 92.61±0.54 86.19±0.31 88.54±0.30 
40 89.76±0.54 92.20±0.31 82.50±0.31 87.03±0.53 
50 89.52±0.62 92.34±0.32 82.58±0.00 84.79±0.54 
60 90.18±0.54 91.75±0.32 82.30±0.30 83.25±0.62 
         n=3* 
TABLE 7B: IN VITRO RELEASE PROFILE OF TORSEMIDE FAST 
DISSOLVING TABLETS 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
F5 
 
F6 
 
F7 
 
F8 
 
5 56.80±0.31 57.71±0.54 62.04±0.31 59.33±0.54 
10 90.53±0.54 88.55±0.31 96.34±0.31 91.99±0.31 
15 88.69±0.31 88.50±0.30 95.79±0.54 91.78±0.31 
20 88.09±0.31 88.08±0.31 95.78±0.54 91.38±0.31 
25 87.49±0.31 87.84±0.31 96.12±0.54 90.98±0.54 
30 86.88±0.31 85.43±0.54 95.92±0.94 89.67±0.31 
40 86.63±0.31 84.81±0.54 95.90±0.55 89.07±0.31 
50 85.11±0.82 83.82±0.31 95.33±0.55 88.46±0.32 
60 82.49±0.53 82.10±0.32 94.22±0.84 87.67±0.30 
         n=3* 
 TABLE 7C: IN VITRO RELEASE PROFILE OF TORSEMIDE FAST 
DISSOLVING TABLETS 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
F9 
 
F10 
 
F11 
 
F12 
 
5 64.93±0.54 60.42±0.54 61.50±0.54 63.31±0.31 
10 95.09±0.31 92.54±0.31 90.56±0.54 94.00±0.31 
15 93.81±0.30 92.15±0.54 90.34±0.31 93.80±0.54 
20 92.70±0.31 92.11±0.54 89.93±0.54 93.77±0.54 
25 92.67±0.31 91.90±0.63 90.06±0.32 93.56±0.31 
30 92.63±0.54 91.67±0.84 90.19±0.63 93.53±0.32 
40 92.05±0.54 90.91±0.95 89.60±0.63 92.59±0.54 
50 92.00±0.54 89.95±0.85 88.63±0.55 91.83±0.83 
60 91.77±0.55 89.17±0.55 87.84±0.32 90.69±0.84 
         n=3* 
TABLE 7D: IN VITRO RELEASE PROFILE OF TORSEMIDE FAST 
DISSOLVING TABLETS 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
F13 
 
F14 
 
F15 
 
F16 
 
5 55.90±0.31 59.51±0.31 62.04±0.54 52.83±0.54 
10 84.75±0.31 88.20±0.31 92.73±0.54 84.91±0.31 
15 85.76±0.82 88.33±1.74 91.62±0.54 85.20±0.62 
20 86.59±0.54 87.91±0.31 90.50±0.94 85.85±1.25 
25 87.43±0.63 87.67±0.00 90.09±1.14 86.68±1.66 
30 88.26±0.84 88.15±0.00 89.67±0.84 86.97±0.94 
40 89.10±0.95 88.44±0.62 88.17±0.56 87.81±0.64 
50 89.77±0.95 88.38±0.62 86.66±0.61 87.92±0.02 
60 90.43±0.95 88.67±0.83 85.14±0.30 88.57±0.60 
         n=3* 
 TABLE 7E: IN VITRO RELEASE PROFILE OF TORSEMIDE FAST 
DISSOLVING TABLETS 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
F17 
 
F18 
 
F19 
 
F20 
 
5 58.61±0.31 52.65±0.31 62.04±0.54 61.14±0.31 
10 91.27±0.31 86.54±0.31 92.55±0.31 89.65±0.31 
15 91.23±0.31 87.02±0.31 92.52±0.31 89.79±0.31 
20 90.29±0.31 88.22±0.54 92.85±0.31 90.28±0.31 
25 89.34±0.00 88.88±0.31 92.45±0.62 90.78±0.31 
30 88.20±0.54 88.46±0.63 92.59±0.53 90.55±0.31 
40 87.95±0.31 89.12±0.01 92.01±0.54 90.50±0.83 
50 87.16±0.30 89.78±0.32 92.15±0.30 90.44±0.84 
60 84.92±0.31 90.62±0.01 92.46±0.00 90.57±0.31 
         n=3* 
TABLE 7F: IN VITRO RELEASE PROFILE OF TORSEMIDE FAST 
DISSOLVING TABLETS 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
F21 
 
F22 
 
F23 
 
F24 
 
5 64.39±0.31 59.33±0.54 58.79±0.54 59.69±0.82 
10 92.74±0.54 90.00±0.54 89.10±0.31 90.01±0.54 
15 91.45±0.30 87.97±0.30 89.59±0.31 89.42±0.54 
20 90.69±0.82 86.83±0.31 90.45±0.53 89.19±1.57 
25 88.84±0.54 84.96±0.53 91.48±0.54 89.14±0.64 
30 88.24±0.54 83.25±0.54 91.80±1.12 88.36±1.27 
40 87.81±0.31 81.00±0.54 92.66±0.63 88.11±1.45 
50 85.21±0.31 78.72±0.54 93.16±0.32 86.96±1.46 
60 84.94±0.32 76.97±0.55 93.84±0.82 86.16±1.16 
         n=3* 
  
 
 
 
 
TABLE 7G: IN VITRO RELEASE PROFILE OF TORSEMIDE FAST 
DISSOLVING TABLETS 
TIME IN 
MINUTES 
 
CUMULATIVE PERCENTAGE DRUG RELEASE ± SD* 
F25 
 
F26 
 
F27 
 
F28 
 
5 62.40±0.31 61.14±0.31 66.92±0.54 10.57±0.54 
10 95.98±0.54 93.81±0.54 99.62±0.31 22.36±0.82 
15 96.33±0.83 93.79±0.54 99.45±0.31 34.77±0.62 
20 95.42±1.09 93.40±0.31 99.27±0.00 44.35±0.83 
25 93.95±0.32 93.19±0.54 99.28±0.00 53.99±0.55 
30 93.38±0.29 92.97±0.31 99.27±0.00 64.04±0.55 
40 91.36±0.61 92.39±0.31 98.91±0.31 75.77±0.94 
50 90.04±0.82 92.35±0.32 98.36±0.30 90.81±0.55 
60 89.26±0.53 91.22±0.32 97.80±0.31 95.82±0.62 
         n=3* 
 
 
 
 
 
 
 
 
  
 
 
 
TABLE 8A: STABILITY STUDY OF BEST FORMULATION (F27) AT 
40° C ± 2°C AND 75%± 5% 
 
 
 
 
 
 
 
 
 
 
PARAMETERS 
 
INTERVAL OF TESTING 
 
AT 0 MONTH 
 
AT 1MONTH 
 
AT 2MONTH 
 
Physical 
appearance 
White colour White colour White colour 
 
Hardness 
(kg/cm2) 
3 3 3 
 
Thickness (mm) 
 
3 3 3 
Wetting time 
(sec)±SD* 10 14 15 
Water absorption 
ratio(%)±SD* 91.90±0.57 91.39±0.59 91.20±0.43 
Disintegration 
time (sec)±SD* 53 56 57 
 
Drug content 
(%)±SD* 
97.98±0.15 97.38±0.76 97.15±0.42 
  
 
 
 
TABLE 8B: DISSOLUTION PROFILE OF BEST FORMULATION (F27) AT 
40° C ± 2°C AND 75%± 5% 
 
Time interval 
(min) 
 
Percentage of drug release (%) ± SD* 
AT 0 MONTH AT 1MONTH AT 2MONTH 
 
5 
 
66.92±0.54 65.65±0.31 65.29±0.54 
 
10 
 
99.62±0.31 98.53±0.31 98.17±0.54 
 
15 
 
99.45±0.31 98.35±0.31 98.17±0.54 
 
20 
 
99.27±0.00 98.17±0.54 97.99±0.32 
 
25 
 
99.28±0.00 98.17±0.54 97.80±0.32 
 
30 
 
99.27±0.00 98.16±0.54 97.79±0.32 
 
40 
 
98.91±0.31 97.61±1.08 97.42±0.83 
 
50 
 
98.36±0.30 97.59±1.09 97.22±0.63 
 
60 
 
97.80±0.31 97.03±0.55 96.83±0.32 
                    n=3* 
     
 
 
 
 
 
Figure 3:  Determination of λmax of Torsemide 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 4:  Calibration curve of Torsemide in 0.1N HCl 
 
 
 
 
 
 
 
 Figure 5a: FT-IR spectrum of Torsemide 
 
 
Figure 5b: FT-IR spectrum of sodium starch glycolate 
 Figure 5c: FT-IR spectrum of croscarmelose sodium 
 
 
Figure 5d: FT-IR spectrum of crospovidone 
 
 
Figure 5e: FT-IR spectrum of microcrystalline cellulose 
 
 
Figure 5f: FT-IR spectrum of sodium lauryl sulphate 
 
 
 Figure 5g: FT-IR spectrum of Torsemide + sodium starch glycolate + 
microcrystalline cellulose + sodium lauryl sulphate 
 
 
Figure 5h: FT-IR spectrum of Torsemide + croscarmelose sodium + 
microcrystalline cellulose + sodium lauryl sulphate 
 
 Figure 5i: FT-IR spectrum of Torsemide + crospovidone + microcrystalline 
cellulose + sodium lauryl sulphate 
 
 
Figure 5j: FT-IR spectrum of Torsemide fast dissolving tablet 
 Figure 6a: DSC thermogram of Torsemide 
 
 
 
Figure 6b: DSC thermogram of sodium starch glycolate 
 
 Figure 6c: DSC thermogram of croscarmelose sodium 
 
 
 
Figure 6d: DSC thermogram of crospovidone 
 Figure 6e: DSC thermogram of microcrystalline cellulose 
 
 
 
Figure 6f: DSC thermogram of sodium lauryl sulphate 
  
 
 
 
 
 
 
 
 
Figure 6g: DSC thermogram of Best formulation 
 
 
 
 
 
 
     
    
    
Figure 7: Wetting time for fast dissolving tablet (F27) 
 
 
                                                
                                                 
                                                                                               
Figure 8: Disintegration time for fast dissolving tablet (F27) 
  
Figure 9a: Comparison of Invitro release profile of Torsemide containing different percentage of Sodium Starch Glycolate 
 
 
  
Figure 9b: Comparison of Invitro release profile of Torsemide containing different percentage of Croscarmellose Sodium 
 
 
  
Figure 9c: Comparison of Invitro release profile of Torsemide containing different percentage of Crospovidone 
 
 
  
Figure 9d: Comparison of invitro release profile of Torsemide containing different super disintegrants and without super disintegrants 
 
 
  
Figure 10: Comparison of in vitro dissolution profile (F27) of 0 month, 1 month and 2months (stored at 40o C±2o C and RH 75 %±5%) 
 
  
Figure 11a: Powder X-ray diffraction studies for Torsemide 
 
 
  
Figure 11b: Powder X-ray diffraction studies for sodium starch glycolate 
 
 
  
Figure 11c: Powder X-ray diffraction studies for croscarmellose sodium 
 
 
  
Figure 11d: Powder X-ray diffraction studies for crospovidone 
 
  
Figure 11e: Powder X-ray diffraction studies for microcrystalline cellulose 
 
 
  
Figure 11f: Powder X-ray diffraction studies for sodium lauryl sulphate 
 
 
  
Figure 11g: Powder X-ray diffraction studies for Best formulation
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CHAPTER – X 
SUMMARY AND CONCLUSION 
 The purpose of the study was to formulate and evaluate Fast Dissolving Tablets of 
Torsemide. 
 The results of Fourier Transmission Infra-Red spectroscopy confirm that both 
drug and excipients are compatible with each other and are devoid of interactions. 
 The results of precompression studies like angle of repose, bulk density, tapped 
density, compressibility index and hausner’s ratio reveals that the prepared 
powder blends of all formulations possess good flow properties. 
 The tablets were prepared by direct compression method using super disintegrants 
like Sodium starch glycolate (F1 to F9), Croscarmallose sodium (F10 to F18) 
Crospovidone (F19 to F27) and  without superdisintegrant (F28)  in different 
concentrations of 2%,4%,6%,8%,10%,12%,14%,16%,18%. Mannitol is used as 
both binder and sweetener, sodium saccharin for additional taste masking and 
microcrystalline cellulose as diluent. The tablets obtained were of uniform shape 
and size. 
 The prepared tablets were subjected to post compression evaluations and the 
results indicate that the hardness, thickness and diameters of all the tablets are 
uniform, which ensures that all the tablets were of uniform size and shape with 
good resistance against mech anical damage. 
 The tablets of all formulations contains uniform amount of drug, which ensures 
content uniformity for tablets of all formulations. 
 The tablets were within the limits of weight variation test, which in turn indicate 
uniform distribution of contents of the powder blends of each formulations. 
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 The friability of all the tablets was found to be < 1%, which indicates the good 
mechanical resistance. 
 The tablets of all formulations were found to have minimum wetting time and 
maximum water absorption ratio which is the desired characteristic of fast 
dissolving tablets, which enables faster disintegration of tablets. 
 The disintegration time of all tablets were found to be less than three minutes, 
which ensures faster disintegration except formulations (F28). 
 The tablets of all the formulations were found to release more than 80% in 10 
minutes, which is the desired quality of fast dissolving tablets that helps in faster 
absorption of the drug and quick onset of therapeutic effect except for 
formulations (F28). The dissolution pattern of various disintegrants used in the 
formulations was found to be in the order of Crospovidone > Sodium starch 
glycolate > Croscarmallose sodium. 
 The DSC thermogram of Torsemide and final formulation, the sharp endothermic 
peak of pure drug appeared at 167.97oC, whereas final formulation appeared at 
168.31oC, which indicates that there was no interaction between drug and 
excipients. 
 The results of the powder X- ray diffraction studies proved that the crystallinity of 
pure drug was remarkably reduced in the best formulation. 
 The selected formulation was found to be stable under the storage condition. 
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CONCLUSION 
In present study, the fast dissolving tablet of torsemide, an anti-hypertensive 
drug was formulated with an objective to improve patient compliance and achieve 
rapid onset of action. Three different super disintegrants sodium starch glycolate, 
croscarmellose sodium and crospovidone were used in formulations. Formulation F27 
containing 18% crospovidone has shown the better results for disintegration time of 
53 seconds. In-vitro dissolution study showed 99.62% of drug release at the end of 10 
minutes. The overall results shows F27 formulation was excellent. Stability study 
shows that there was no significant change in the selected formulation. Thus 
Crospovidone can be successfully used in the formulation of fast dissolving tablets. 
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